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A B S T R A C T
Background
Gliomas are brain tumours arising from glial cells with an annual incidence of 4 to 11 people per 100,000. In this review we focus
on gliomas with low aggressive potential in the short term, i.e. low-grade gliomas. Most people with low-grade gliomas are treated
with surgery and may receive radiotherapy thereafter. However, there is concern about the possible long-term effects of radiotherapy,
especially on neurocognitive functioning.
Objectives
To evaluate the long-term neurocognitive and other side effects of radiotherapy (with or without chemotherapy) compared with no
radiotherapy, or different types of radiotherapy, among people with glioma (where ’long-term’ is defined as at least two years after
diagnosis); and to write a brief economic commentary.
Search methods
We searched the following databases on 16 February 2018 and updated the search on 14 November 2018: Cochrane Central Register of
Controlled Trials (CENTRAL; 2018, Issue 11) in the Cochrane Library; MEDLINE via Ovid; and Embase via Ovid. We also searched
clinical trial registries and relevant conference proceedings from 2014 to 2018 to identify ongoing and unpublished studies.
Selection criteria
Randomised and non-randomised trials, and controlled before-and-after studies (CBAS). Participants were aged 16 years and older
with cerebral glioma other than glioblastoma. We included studies where patients in at least one treatment arm received radiotherapy,
with or without chemotherapy, and where neurocognitive outcomes were assessed two or more years after treatment.
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. We assessed the certainty of findings using the GRADE
approach.
Main results
The review includes nine studies: seven studies were of low-grade glioma and two were of grade 3 glioma. Altogether 2406 participants
were involved but there was high sample attrition and outcome data were available for a minority of people at final study assessments.
In seven of the nine studies, participants were recruited to randomised controlled trials (RCTs) in which longer-term follow-up was
undertaken in a subset of people that had survived without disease progression. There was moderate to high risk of bias in studies due
to lack of blinding and high attrition, and in two observational studies there was high risk of selection bias. Paucity of data and risk
of bias meant that evidence was of low to very low certainty. We were unable to combine results in meta-analysis due to diversity in
interventions and outcomes.
The studies examined the following five comparisons.
Radiotherapy versus no adjuvant treatment
Two observational studies contributed data. At the 12-year follow-up in one study, the risk of cognitive impairment (defined as cognitive
disability deficits in at least five of 18 neuropsychological tests) was greater in the radiotherapy group (risk ratio (RR) 1.95, 95%
confidence interval (CI) 1.02 to 3.71; n = 65); at five to six years the difference between groups did not reach statistical significance
(RR 1.38, 95% CI 0.92 to 2.06; n = 195). In the other study, one subject in the radiotherapy group had cognitive impairment (defined
as significant deterioration in eight of 12 neuropsychological tests) at two years compared with none in the control group (very low
certainty evidence).
With regard to neurocognitive scores, in one study the radiotherapy group was reported to have had significantly worse mean scores on
some tests compared with no radiotherapy; however, the raw data were only given for significant findings. In the second study, there
were no clear differences in any of the various cognitive outcomes at two years (n = 31) and four years (n = 15) (very low certainty
evidence).
Radiotherapy versus chemotherapy
One RCT contributed data on cognitive impairment at up to three years with no clear difference between arms (RR 1.43, 95% CI
0.36 to 5.70, n = 117) (low-certainty evidence).
High-dose radiotherapy versus low-dose radiotherapy
Only one of two studies reporting this comparison contributed data, and at two and five years there were no clear differences between
high- and low-dose radiotherapy arms (very low certainty evidence).
Conventional radiotherapy versus stereotactic conformal radiotherapy
One study involving younger people contributed limited data from the subgroup aged 16 to 25 years. The numbers of participants
with neurocognitive impairment at five years after treatment were two out of 12 in the conventional arm versus none out of 11 in the
stereotactic conformal radiotherapy arm (RR 4.62, 95% CI 0.25 to 86.72; n = 23; low-certainty evidence).
Chemoradiotherapy versus radiotherapy
Two RCTs tested for cognitive impairment. One defined cognitive impairment as a decline of more than 3 points in MMSE score
compared with baseline and reported data from 2-year (110 participants), 3-year (91 participants), and 5-year (57 participants) follow-
up with no clear difference between the two arms at any time point. A second study did not report raw data but measured MMSE
scores over five years in 126 participants at two years, 110 at three years, 69 at four years and 53 at five years. Authors concluded that
there was no difference in MMSE scores between the two study arms (P = 0.4752) (low-certainty evidence).
Two RCTs reported quality of life (QoL) outcomes for this comparison. One reported no differences in Brain-QoL scores between
study arms over a 5-year follow-up period (P = 0.2767; no raw data were given and denominators were not stated). The other trial
reported that the long-term results of health-related QoL showed no difference between the arms but did not give the raw data for
overall HRQoL scores (low-certainty evidence).
We found no comparative data on endocrine dysfunction; we planned to develop a brief economic commentary but found no relevant
economic studies for inclusion.
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Authors’ conclusions
Radiotherapy for gliomas with a good prognosis may increase the risk of neurocognitive side effects in the long term; however the
magnitude of the risk is uncertain. Evidence on long-term neurocognitive side effects associated with chemoradiotherapy is also
uncertain. Neurocognitive assessment should be an integral part of long-term follow-up in trials involving radiotherapy for lower-grade
gliomas to improve the certainty of evidence regarding long-term neurocognitive effects. Such trials should also assess other potential
long-term effects, including endocrine dysfunction, and evaluate costs and cost effectiveness.
P L A I N L A N G U A G E S U M M A R Y
Long-term effects of radiotherapy for glioma treatment on brain functioning
Background
Gliomas are brain tumours that can be very aggressive and result in death within months; however, people with less aggressive gliomas
(low-grade gliomas) can survive for a number of years. Most people are treated with surgery and may also receive radiotherapy with
or without chemotherapy. However, radiotherapy can damage healthy brain tissue, and we do not know enough about the possible
long-term effects of radiotherapy on brain functioning, such as memory, communication, concentration and speed of thinking (called
neurocognition). Progression of the tumour can also cause deterioration in brain functioning. In this review we looked at the possible
long-term effects of radiotherapy on the brain in adults with less aggressive gliomas who had survived for at least two years after receiving
treatment.
Methods and results
We searched for relevant research studies up to 14 November 2018. We only included studies with a control group (i.e. studies that
included groups of people that had or had not received radiotherapy or had received different types or doses of radiotherapy). The review
includes nine research studies that collected information on long-term neurocognitive or quality of life outcomes, mostly among people
with low-grade gliomas. Altogether 2406 participants were involved in these studies. The studies looked at five different comparisons
including radiotherapy versus no radiotherapy, radiotherapy versus chemotherapy, high- versus low-dose radiotherapy, different types
of radiotherapy, and radiotherapy versus chemoradiotherapy. Some evidence suggested that radiotherapy might increase the risk of
cognitive impairment compared with no radiotherapy after surgery; however, this and evidence for the other comparisons was not
convincing. This was partly because many of the people were not followed up, either because they had died or their disease had
progressed, and so the resulting evidence was weak.
No studies compared effects of radiotherapy on relevant hormone functioning; we planned to develop a brief economic commentary
to summarise information on whether the interventions represented a good use of health services but found no relevant studies.
Conclusions
The risk of long-term deterioration in brain functioning associated with radiotherapy for the treatment of less aggressive gliomas remains
uncertain. Further research on glioma treatment options should assess potential long-term cognitive and hormonal side effects, costs
and value for money.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Long- term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
Patient or population: people with glioma surviving at least two years
Settings: tert iary care
Comparison and Outcomes Relative effect
(95% CI)
No of participants andstudies Quality of the evidence
(GRADE)
Comments
Intervention: radiotherapy
Comparison: no adjuvant treat-
ment
Outcome: neurocognit ive impair-
ment at 5- to 6-year follow-up
RR 1.38 (0.92 to 2.06) 1 study with data for 195 part ici-
pants
⊕©©©
very low1,2
Outcome def ined as cognit ive dis-
ability def icits in at least 5 of 18
neuropsychological tests
Intervention: radiotherapy
Comparison: no adjuvant treat-
ment
Outcome: neurocognit ive impair-
ment at 12 year follow-up
RR 1.95 (1.02 to 3.71) 1 study with data for 65 part ici-
pants
⊕©©©
very low1,3
Outcome def ined as cognit ive dis-
ability def icits in at least 5 of 18
neuropsychological tests
Intervention: radiotherapy
Comparison: no adjuvant treat-
ment
Outcome: neurocognit ive impair-
ment at 2 year follow-up
RR 2.50 (0.11 to 56.98) 1 study with data for 31 part ici-
pants
⊕©©©
very low1,2,3
There was a single event for
this outcome in this observat ional
study. The outcome was def ined
as a signif icant deteriorat ion (≥ 1
SD) in 8 out of 12 neuropsycholog-
ical tests
Intervention: radiotherapy
Comparison: chemotherapy
Outcome: neurocognit ive impair-
ment at 3 year follow-up
RR 1.43 (0.36 to 5.70) 1 study with data for 117 part ici-
pants
⊕⊕©©
low2,3
Outcome def ined as a MMSEscore
of 26 or less
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Intervention: high-dose radio-
therapy
Comparison: low-dose radiother-
apy
Outcome: neurocognit ive impair-
ment at 2 years af ter treatment
RR 0.53 (0.06, 4.85) 1 study with data for 65 part ici-
pants
⊕©©©
very low2,3,4
Outcome def ined as decrease in
MMSE score f rom baseline (more
than 3 points).There was seri-
ous and uneven attrit ion between
groups in this study
Intervention: high-dose radio-
therapy
Comparison: low-dose radiother-
apy
Outcome: neurocognit ive impair-
ment at 5 years af ter treatment
RR 0.16 (0.01 to3.20) 1 study with data for 38 part ici-
pants
⊕©©©
very low2,3,4
Outcome def ined as decrease in
MMSE score f rom baseline (more
than 3 points). There was seri-
ous and uneven attrit ion between
groups in this study
Intervention: chemoradiotherapy
Comparison: radiotherapy
Outcome: neurocognit ive impair-
ment at 3 years af ter treatment
RR 0.37 (0.02 to 8.88) 1 study with data for 91 part ici-
pants
⊕⊕©©
low 2,3
Outcome def ined as a decline (of
more than 3 points in MMSEscore)
in cognit ive state compared with
baseline
Intervention: stereotactic con-
formal radiotherapy
Comparison: radiotherapy
Outcome: neurocognit ive impair-
ment at 5 years af ter treatment
RR 4.62 (95% CI 0.25 to 86.72) 1 study with data for 23 part ici-
pants
⊕⊕©©
low 2,3
Outcome def ined as a decline (of
more than 3 points in MMSEscore)
in cognit ive state compared with
baseline. There was serious sam-
ple attrit ion at 5 years
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
Abbreviat ions: SD = standard deviat ion; MMSE = Mini Mental State Exam
1. Single study contribut ing data had very serious study design lim itat ions (−2)
2. Uncertain f indings; wide 95% CI crossing the line of no ef fect (−1)
3. Ef fect est imate based on small sample size (−1)
4. Single study contribut ing data had study design lim itat ions (−1)
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B A C K G R O U N D
Description of the condition
Primary brain and other central nervous system (CNS) tumours
are less common than many other cancers, accounting for around
1.9% of new cancer diagnoses annually; however, they are associ-
ated with a relatively higher proportion of cancer deaths annually
(2.3%), amounting to approximately 189,382 deaths worldwide
in 2012 (GLOBOCAN 2012). Gliomas are brain tumours that
arise from glial cells, usually oligodendrocytes and astrocytes. They
occur at an annual incidence of four to 11 people per 100,000
and are more frequent in high-income, industrialised countries
(Ohgaki 2009). Gliomas are graded 1 to 4 by the World Health
Organization (WHO) according to their aggressive potential in the
short term. The 2007 WHO classification system (Louis 2007),
used in completed clinical trials since 2007, graded gliomas based
on histological characteristics only. However, in the 2016 WHO
classification system, to be used in future trials, grading depends
on both histological and molecular features, e.g. isocitrate dehy-
drogenase (IDH) status, chromosome 1p 19q, and other genetic
parameters (Louis 2016). Using the 2007 WHO classification,
gliomas graded 1 and 2 have low aggressive potential and are re-
ferred to as low-grade gliomas; these include pilocytic astrocytomas
(grade 1), diffuse astrocytomas, oligodendrogliomas and mixed
oligoastrocytomas (grade 2). High-grade gliomas have faster lo-
cal growth rates and include anaplastic astrocytomas, anaplastic
oligodendrogliomas (grade 3) and glioblastomas (grade 4). Grades
correspond with prognosis: grade 1 has a good prognosis and can
often be cured with surgery alone, whereas grade 4 has a poor
prognosis, and can be rapidly fatal (Louis 2007). Thus, tumour
grade is a key factor in deciding how to treat gliomas, particularly
the need for additional treatment in the form of radiotherapy or
chemotherapy or both (chemoradiotherapy) after surgery.
Description of the intervention
Most people with glioma first undergo surgery to resect (cut out)
or biopsy the tumour. The latter is usually performed when re-
section is not possible, either due to the diffuse, infiltrative nature
of the tumour, or its location near important structures. Addi-
tional radiotherapy targeting the tumour area (focal radiotherapy)
is usually given immediately after surgery for high-grade gliomas,
whereas for grade 2 gliomas it can either be given immediately, or
postponed if the tumour has been resected until the development
of new symptoms or tumour progression (Sarmiento 2015). Fifty
per cent of people with grade 2 and grade 3 gliomas survive at least
seven years and four and a half years, respectively, after treatment
(Buckner 2016; Cairncross 2013). However, for certain grade 2
and 3 gliomas with particular molecular features, median survival
can be extended by a further seven years by the addition of ad-
juvant chemotherapy to radiotherapy (Buckner 2016; Cairncross
2013). Among people with grade 4 gliomas that are treated with
chemoradiotherapy, only approximately 25% are alive two years
after diagnosis (Stupp 2005).
Potential side effects
The treatment of glioma can be complicated by long-term side
effects that present months or years after treatment. This is due
to the exposure of healthy brain tissue to radiation, which ad-
versely affects brain plasticity (the ability of the brain to modify its
connections and rewire) and repair processes (Dhermain 2016).
As the frequency of side effects increases with time, these tend to
be problematic for people with less aggressive tumours who sur-
vive long term, and are especially common among survivors of
childhood brain tumours (Grill 1999; Seaver 1994; Spiegler 2004;
Williams 2018). Certain parts of the brain such as the hippocam-
pus, fornix and corpus callosum are more sensitive to irradiation
(Connor 2017; Gondi 2012; Gondi 2018; Peiffer 2013); impair-
ment of memory, communication, concentration and problem-
solving (neurocognition) can result. Studies among adults with
low-grade glioma show that the risk of neurocognitive impairment
is increased when radiotherapy is administered to the whole brain
(Gregor 1996; Surma-aho 2001), but is less likely when radiother-
apy is administered to the tumour area only (Brown 2003; Laack
2005; Taphoorn 1994; Vigliani 1996). Factors that are important
to the risk of long-term side effects in glioma treatment are the
site of the tumour, the volume of brain tissue irradiated, the radio-
therapy fraction size and the total radiotherapy dose. The use of
chemotherapy with radiotherapy might plausibly add to the risk.
Endocrine (hormonal) dysfunction affecting adrenal (stress re-
sponse) hormones, gonadal (sex) hormones, and thyroid hormones
can also occur due to radiotherapy damage to the hypothalamic-
pituitary axis (Taphoorn 1995), the system that communicates
with hormone-producing glands in the body. Pituitary dysfunc-
tion is commonly diagnosed amongst children who have under-
gone radiotherapy for glioma, which in children frequently leads
to hypothyroidism, growth hormone deficiency, and precocious
puberty (Terashima 2013). In adults, recent studies suggest that
pituitary dysfunction following radiotherapy for brain tumours
is very underdiagnosed and that regular endocrine surveillance
should be performed above a dose threshold of 30 Gy (Kyriakakis
2016; Kyriakakis 2019). In addition, fatigue, disturbed sleep and
depression are also commonly reported side effects of treatment
(Armstrong 2017). Such side effects can seriously interfere with
a person’s ability to work, maintain relationships, perform daily
activities, and enjoy life (Armstrong 2016).
Why it is important to do this review
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Long-term cognitive side effects of radiotherapy were identified
among the top 10 priority research questions in neuro-oncology
by the James Lind Alliance and the National Cancer Research
Institute (NCRI) (JLA 2015). This is because uncertainty exists
about the long-term side effects of radiotherapy for brain tumours,
especially among people with a good prognosis. Evaluating the
long-term consequences of treatment is important to understand
what the real impact of this condition and its treatment are for
individuals and health systems. We undertook this review to help
inform clinical decision making in the context of a trend towards
more aggressive early treatments for low-grade gliomas.
The costs of care can be ’direct costs’ due to health care resources
used to treat the condition, or ’indirect costs’ that are borne by the
patient and their families. Radiotherapy is one of the highest direct
costs of glioma management (Blomqvist 2000; Raizer 2015). The
cost of malignant gliomas has been estimated to range between
USD 50,600 and USD 92,700 (2015) per patient per year (Raizer
2015). It is, therefore, also important to understand the long-term
consequences of different glioma management strategies so that
the costs and consequences of such strategies can be fully evaluated.
O B J E C T I V E S
To evaluate the long-term neurocognitive and other side effects
of radiotherapy (with or without chemotherapy) compared with
no radiotherapy, or different types of radiotherapy, among people
with glioma (where ’long-term’ is defined as at least two years after
diagnosis); and to write a brief economic commentary.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and non-randomised trials, and controlled before-
and-after studies (CBAS). We considered non-randomised trials
and CBAS for inclusion if there were no primary outcome data
from randomised trials for a particular treatment comparison. We
excluded cross-over designs, case-control studies, and studies that
did not have a control group.
Types of participants
People aged 16 years of age and older with a histopathologically
confirmed diagnosis of cerebral glioma who are alive at least two
years after diagnosis.
In this review, as we considered late effects to be those that are
present at two years or more after diagnosis among people who
have a good long-term prognosis, rather than in those that have a
short-term prognosis, we excluded studies only involving people
with glioblastoma. In studies with mixed high-grade glioma par-
ticipants (grade 3 and grade 4 gliomas) we planned to extract data
for the participants with grade 3 glioma only where possible.
Types of interventions
Treatment interventions after surgery (biopsy or resection of the
tumour) could include the following.
• Radiotherapy compared with no radiotherapy, which
includes the following comparison subgroups.
◦ Radiotherapy versus no adjuvant treatment.
◦ Chemoradiotherapy versus no adjuvant treatment.
◦ Radiotherapy versus chemotherapy.
◦ Chemoradiotherapy versus chemotherapy.
• High-dose radiotherapy versus low-dose radiotherapy.
• Conventional radiotherapy versus conformal radiotherapy
• Chemoradiotherapy versus radiotherapy.
Types of outcome measures
Studies had to report at least one of the primary outcomes in
both the intervention and control groups at least two years after
receiving the intervention.
Primary outcomes
• Cognitive impairment (objective or subjective), as
measured by an overall cognitive function score, a change over
time score, or as a categorical outcome. This includes evaluation
of cognitive impairment as individual cognitive function
domains, e.g. verbal fluency, processing speed, memory,
attention, and executive functioning, using a standardised
measurement tool, e.g. Mini Mental State Exam (MMSE),
Cognitive Failures Questionnaire (CFQ).
• Quality of life (QoL), as measured using a standardised
questionnaire, e.g. the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 or QLQ-BN20
(specific for brain cancer), or the Functional Assessment of
Cancer Therapy scale (FACT-G (general) or FACT-Br (specific
for brain cancer)).
Secondary outcomes
• Functional impairment or disability, as measured by an
overall ability score, or as a change of ability over time score, or
both, using a standardised measurement tool, e.g. Karnofsky
Performance Status Scale, Neurological Functions Score; or as a
categorical outcome, as defined by investigators.
• Endocrine dysfunction, as determined by use of hormonal
treatment, or as defined by study investigators, or both.
• Depression, as measured by a standardised scale, e.g.
Hospital Anxiety and Depression Scale (HADS).
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• Anxiety, as measured by a standardised scale, e.g. HADS.
• Fatigue, according to Common Terminology Criteria for
Adverse Events (CTCAE), or as defined by investigators.
• Sleep disturbances, as defined by investigators.
• Imaging evidence of physical deficit, e.g. general brain
atrophy, white matter changes, radionecrosis, stroke.
• Social outcomes (e.g. carer strain, relationship status,
employment status).
• Second cancers.
We present evidence regarding cost of care as a brief economic
commentary.
Search methods for identification of studies
Electronic searches
We searched the following databases on the 16 February 2018 and
updated the search on 14 November 2018.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 11), in the Cochrane Library;
• MEDLINE via Ovid (1946 to October week 5 2018);
• Embase via Ovid (1980 to 2018 week 46).
Please refer to Appendix 1 for CENTRAL, MEDLINE and Em-
base search strategies.
We did not apply language restrictions to any of the searches.
Searching other resources
We searched the following for ongoing trials.
• ClinicalTrials.gov;
• International Clinical Trials Registry Platform (ICTRP) (
apps.who.int/trialsearch).
Where we identified through these searches ongoing trials that had
not been published, we approached the principal investigators to
ask for an update on the trial status and relevant data. We used the
related articles feature of PubMed and handsearched the reference
lists of included studies to identify newly published articles and
additional studies of relevance. We also handsearched conference
proceedings from 2014 to 2018 (5 years) of conferences of the
British Neuro-Oncology Society, the Society for Neuro-Oncol-
ogy, the European Association of Neuro-Oncology and the World
Federation of Neuro-Oncology Societies for relevant ongoing or
unpublished studies.
Data collection and analysis
Selection of studies
The Information Specialist at the Cochrane Gynaecological,
Neuro-oncology and Orphan Cancer Group (GNOC) down-
loaded all titles and abstracts retrieved by electronic searching to
Endnote and removed duplicates and those studies that clearly did
not meet the inclusion criteria. Review authors in teams of two
(TL and RG; JE and DG) independently screened the remaining
records and excluded studies that clearly did not meet the inclu-
sion criteria. We obtained copies of the full texts of potentially
eligible references and at least two review authors independently
assessed these for eligibility (TL and RG, JE or DG). The two re-
view authors concerned resolved disagreements by discussion and,
if necessary, consulted the other review authors. We used Covi-
dence to facilitate this study selection process (Covidence 2018),
and document reasons for exclusion in Characteristics of excluded
studies.
Data extraction and management
Two review authors (TL, TD, RG, JE or DG) independently ex-
tracted the following data from included studies to a pre-designed
data extraction form.
• Author contact details
• Country
• Setting
• Dates of participant accrual
• Trial registration number/identification
• Funding source
• Participant inclusion and exclusion criteria
• Study design and methodology
• Study population and baseline characteristics
◦ Number of participants enrolled/analysed
◦ Age
◦ Gender
◦ Tumour grade/type
◦ Type of surgery (biopsy or resection)
◦ Other medication, e.g. anti-epileptics and anti-
depressants (selective serotonin reuptake inhibitors (SSRIs))
• Intervention details
◦ Type of intervention
◦ Type of comparator
• Duration of follow-up
• Primary outcome/s of the study
• Review outcomes
◦ For dichotomous outcomes, we extracted the number
of participants in each treatment arm who experienced the
outcome of interest and the number of participants assessed
◦ For continuous outcomes, we extracted the value and
standard deviation of the outcome of interest and the number of
participants assessed at the relevant time point in each group. We
also extracted change-from-baseline score data where reported
and noted the type of scale used
◦ We extracted adjusted statistics where reported
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◦ Where possible, all data we extracted were those
relevant to an intention-to-treat analysis, in which participants
were analysed in the groups to which they were assigned
◦ We resolved differences between reviewers by
discussion or by appeal to the other review authors when
necessary
• Risk of study bias (see below)
Assessment of risk of bias in included studies
For randomised trials, we assessed the risk of bias using Cochrane’s
tool and the criteria specified in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). This includes as-
sessment of:
• random sequence generation;
• allocation concealment;
• blinding of participants and healthcare providers;
• blinding of outcome assessors;
• incomplete outcome data (more than 20% missing data
considered high risk);
• selective reporting of outcomes;
• other possible sources of bias, e.g. lack of a power
calculation, baseline differences in group characteristics.
For non-randomised studies (non-randomised trials and CBAS),
we assessed the risk of bias in accordance with four criteria concern-
ing sample selection comparability of treatment groups, namely:
• relevant details of criteria for assignment of people with the
condition to treatments;
• representative group of people with the condition who
received the experimental intervention;
• representative group of people with the condition who
received the comparison intervention;
• baseline differences between groups controlled for, in
particular with reference to age, gender, type and grade of glioma
and surgical treatment.
At least two review authors (TL and at least one other) assessed
risk of bias independently and resolved differences by discussion
or by appeal to a third review author. We summarised judgements
in ’Risk of bias’ tables along with the characteristics of the included
studies. We interpreted results in light of the ’Risk of bias’ assess-
ment. For more details about the assessment of risk of bias, see
Appendix 2.
Measures of treatment effect
• For dichotomous outcomes, we calculated the effect size as
a risk ratio (RR) with its 95% confidence interval (CI).
• For continuous outcomes (e.g. QoL scores) in which
different measurement scales had been used, we did not pool
data because time points, scales and measurement scales were too
dissimilar to produce clinically meaningful estimates of effect.
Unit of analysis issues
At least two review authors (TL, TD) reviewed unit-of-analysis
issues, as described in Higgins 2011, for each included study. These
included reports where there were multiple observations for the
same outcome, e.g. repeated measurements with different scales,
or outcomes measured at different time points to those stipulated
in the review protocol. Because data were sparse, after discussion
amongst the authors we agreed to include data from different scales
and time points and report the findings narratively.
Dealing with missing data
We did not impute missing data. In the event of missing data,
we wrote to study authors to request the data and described in
the Characteristics of included studies tables how we obtained any
missing data. Where substantial volumes of data were missing, we
took this into consideration in our grading of the evidence (see
Data synthesis).
Assessment of heterogeneity
We did not pool data and assessed heterogeneity between stud-
ies by visual inspection of forest plots, where this was meaningful
(Higgins 2003). As no data were pooled, we did not use a for-
mal statistical test of the significance of the heterogeneity (Deeks
2001). Where there was evidence of substantial heterogeneity on
visual inspection of the forest plots, we investigated and reported
the possible reasons for this.
Assessment of reporting biases
Due to few included studies and limited data, it was not possible
to use funnel plots to investigate reporting biases.
Data synthesis
We did not conduct meta-analyses because data were sparse and
comparisons and time points and measurements were too dissim-
ilar for pooled estimates to be clinically meaningful. However, to
help visualise the data and facilitate narrative syntheses, we cre-
ated forest plots for the primary outcomes using Review Manager
5 (RevMan 5) (Review Manager 2014). For future meta-analy-
ses, we will use the random-effects model with inverse variance
weighting. If any trials contributing to a meta-analysis have mul-
tiple intervention groups, we will divide the ’shared’ comparison
group into the number of treatment groups and comparisons be-
tween each treatment group and treat the split comparison group
as independent comparisons. We will perform a meta-analysis of
the results assuming that we find at least two included studies that
are sufficiently similar for the findings to be clinically meaningful.
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’Summary of findings’ table and reporting of results
Based on the methods described in Chapter 11 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
we prepared Summary of findings for the main comparison to
present the results of the primary outcomes, namely:
• cognitive impairment at ≥ 2 years.
• quality of life (QoL) score at ≥ 2 years.
We used the GRADE system to rank the quality of the evidence
(Schünemann 2011). Two review authors independently graded
the evidence. We resolved differences by discussion and, if nec-
essary, by involving a third review author. Where the evidence
was based on single studies, or where there was no evidence on a
specific outcome, we included the outcome in the ’Summary of
findings’ table and graded or explained accordingly. In addition,
we provided a rationale for each judgement of assumed risk in the
table footnotes. In the absence of a single estimate of effect (when
meta-analysis was not possible), we rated the certainty of the effect
using the GRADE approach (Murad 2017). We interpreted the
results of the graded evidence based on Cochrane Effective Prac-
tice and Organisation of Care guidance (EPOC 2017).
Brief economic commentary
A brief economic commentary was planned to summarise the avail-
ability and principal findings of the economic evaluations rele-
vant to this review. This included evaluations alongside trials and
model based evaluations. The work was performed in line with
current guidelines, including a supplementary search to identify
economic studies (Shemilt 2018).
Subgroup analysis and investigation of heterogeneity
For the comparison ’radiotherapy versus no radiotherapy’, we sub-
grouped studies according to the type of control group. However,
as we did not pool the data we were unable to use formal tests for
subgroup differences to determine whether the effect of interven-
tions differ according to these subgroups.
Sensitivity analysis
In this version of the review, we have not performed sensitivity
analysis because data were sparse. In future versions of this review,
when more data are available, we plan to perform sensitivity anal-
yses to investigate substantial heterogeneity identified in meta-
analyses of the primary outcomes, and also to estimate the effect
after excluding studies at high risk of bias, to investigate how study
quality affects the certainty of findings.
R E S U L T S
Description of studies
Results of the search
Initial database searches conducted on the 16 February 2018
yielded the following results:
• CENTRAL Issue 2 2018 621 references
• Medline: 1946 to February week 2 2018 2302 references
• Embase: 1980 to 2018 week 07 2547 references
After de-duplication and filtering out clearly irrelevant papers (e.g.
studies of other cancers), we screened a total of 3197 references
(including 10 references identified using the PubMed related-arti-
cles feature) and short-listed 57 references for full-text screening.
After full-text screening, we classified 19 references (related to 9
studies) as included, 37 as excluded, and one as ongoing (Figure
1).
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Figure 1. Study flow diagram (date of search 16/02/18).
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The top-up search in November 2018 yielded the following:
• CENTRAL Issue 11, 2018 95 additional references
• Medline: February 2018 to October week 5 2018 95
references
• Embase: February 2018 to 2018 week 46 126 references
We identified one additional study by searching the abstracts
from conference proceedings. After de-duplication, we screened
283 additional records plus the one conference abstract on ti-
tle and abstract. This led to our assessment of eight full texts,
seven of which we excluded and one (the conference abstract) we
added to ’Characteristics of ongoing studies’ (Figure 2). We iden-
tified four other potentially eligible ongoing studies by search-
ing the clinical trials registries (NCT00457210; NCT02544178;
NCT03055364; NCT03180502); and we identified one in the
initial database search (CATNON 2017). We subsequently iden-
tified two related publications and added them to the related pre-
viously included studies.
12Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Study flow diagram (date of search 9/10/18).
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Included studies
The review includes nine studies that collected data on long-term
neurocognitive or quality of life outcomes: seven were conducted
among people with low-grade gliomas (Brown 2003; Jalali 2017;
Kiebert 1998 - EORTC 22844; Klein 2002/Douw 2009; Prabhu
2014 - RTOG 9802; Reijneveld 2016 - EORTC 22033-26033;
Vigliani 1996); and two among people with grade 3 gliomas (
Taphoorn 2007 - EORTC 26951; Wang 2010 - RTOG 9402). Of
these nine studies, seven were randomised controlled trials (RCTs),
which is to say that patients were randomly allocated to alternative
treatments at recruitment. As the focus of this review is on long-
term outcomes, such outcome data derived from RCTs was from
those subgroups of participants that survived and were able to
complete long-term assessments. Therefore, because participants
with disease progression or who died were not followed up, the
long-term data from these trials are unlikely to be representative
of the original randomised samples.
Two of the studies were observational (Klein 2002/Douw 2009;
Vigliani 1996), with no attempt to randomly allocate participants
to different treatments - patients receiving different treatments
(physician or institution allocated) were simply followed up over
time. Both of these studies reported outcomes in patients that had
or had not received radiotherapy as part of their treatment for
glioma.
Two studies (Klein 2002/Douw 2009; Taphoorn 2007) reported
further long-term data among survivors as a whole rather than
by treatment group (Boele 2015; Habets 2014, respectively). We
discuss these in more detail in the Agreements and disagreements
with other studies or reviews section of the Discussion).
Numbers recruited and analysed
Altogether 2406 participants were recruited to the nine included
studies. However, in all studies the number included in the analysis
at various time points during follow-up was generally considerably
less than the total recruited or that had undergone baseline assess-
ments. There was serious sample attrition due to death or disease
progression, and there were missing data due to failure to carry out
assessments or low participant response rates. In the Kiebert 1998
study the number followed up beyond two years was not clear; for
the remaining studies, data were available for 503 participants (i.e.
approximately a quarter of those recruited) at the final reported
assessments, the timing of which varied between studies. In the
Brown 2003 study, of 211 recruited there were follow-up data for
97 at one year, 65 at two years and for only 38 at five years. Of 195
recruited to the Klein 2002/Douw 2009 study, data were avail-
able for 65 at the study end point with follow-up times varying
considerably for individual participants. Of 254 randomised in
Prabhu 2014, MMSE data were available for 131 participants at
one year and for 126 at two years; while for the 477 participants
in Reijneveld 2016, data were reported for 253 at one year, 172
at two years and for 117 at three years. In Taphoorn 2007, of 268
randomised 149 were alive and progression-free at 2.5 years and
data were available for 94 of these patients. At four years there were
data for 11 out of 31 participants in the Vigliani 1996 study; and
at five years, of the 291 randomised in the Wang 2010 trial only
29 neurocognitive assessments were available. Finally, we included
one study that recruited children, adolescents and young adults
(Jalali 2017). This study included some participants with other
types of brain tumour including craniopharyngioma, although the
majority had glioma. We were only able to include data for a rel-
atively small proportion of the sample; while 200 were recruited,
only 66 were aged over 16 years and are included in the review, and
at five years (the time point reported) only 23 provided outcome
data.
Location of studies
Three studies were international and recruited patients from in-
stitutions in several countries (Kiebert 1998; Reijneveld 2016;
Taphoorn 2007). The study by Wang 2010 was conducted in hos-
pitals in the USA and Canada. The trials by Brown 2003 and
Prabhu 2014 were carried out in the USA, and the remaining stud-
ies were carried out in the Netherlands (Klein 2002/Douw 2009),
India (Jalali 2017), and France (Vigliani 1996).
Dates of recruitment
Participants were recruited to the various studies between 1985
and 2012, and follow-up in some of the later studies continues.
Three studies began recruitment in the 1980s (Brown 2003 1986
to 1996; Kiebert 1998 1985 to 1991; Vigliani 1996 1989 to 1993);
four in the 1990s (Klein 2002/Douw 2009 1997 to 2000; Prabhu
2014 1998 to 2002; Taphoorn 2007 1996 to 2002; and Wang
2010 1994 to 2002); and two studies started recruitment after
2000 (Jalali 2017 2001 to 2012; Reijneveld 2016 2005 to 2012).
In some studies recruitment was over a long period and it is pos-
sible that screening and diagnosis techniques, research personnel,
aspects of care and adjuvant therapies changed over the course of
the study.
Funding and conflict of interest
In the Kiebert 1998 study sources of funding were not reported.
For the rest, all studies reported being financially supported by
government, cancer charities or higher education research grants
(Brown 2003; Jalali 2017; Klein 2002/Douw 2009; Prabhu 2014;
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Reijneveld 2016; Taphoorn 2007; Vigliani 1996; Wang 2010). In
addition, three trials reported that they had received some sup-
port from commercial or private institutes (Klein 2002/Douw
2009; Reijneveld 2016; Taphoorn 2007). While in the Prabhu
2014 study it was reported that there was no commercial fund-
ing, several of the investigators reported receiving compensation
from commercial organisations, although it was not clear whether
this funding related to the reported work. Where conflict of inter-
est was mentioned, no study authors reported conflict of interest
other than Prabhu 2014 as stated above.
Characteristics of study participants
Age
All but one of the studies recruited only adult participants (> 18
years, although Kiebert 1998 recruited adults > 16 years). One
study recruited children, adolescents and young adults up to the
age of 25 years (Jalali 2017); approximately a third of the sample
in this study were over 16 years and we have only included these
young adults in our data and analysis. Vigliani 1996 had an upper
age limit of 60 years for participants, whereas the remaining studies
included older adults. For the eight studies recruiting adults, the
median age of participants was between 40 and 49 years.
Gender
In most studies there was a larger proportion of male to female
participants (approximately 60:40); In Kiebert 1998 and Vigliani
1996 there were similar numbers of men and women recruited.
Type and grade of glioma
Most studies recruited patients with low-grade glioma and had
criteria that excluded patients with other serious disease (e.g. other
cancers or serious heart, liver or renal problems).
Five studies recruited participants affected by grades 1 or 2 supra-
tentorial glioma including astrocytoma, oligodendroglioma or
mixed disease (Brown 2003; Kiebert 1998; Klein 2002/Douw
2009; Prabhu 2014; Reijneveld 2016). Vigliani 1996 reported re-
cruiting patients with grade 2 or 3 glioma (and in this non-ran-
domised study there was disparity between treatment groups in the
type and grade of disease); and in the Wang 2010 and Taphoorn
2007 trials, participants had grade 3 disease and this was reflected
in the poorer prognosis for patients in these studies compared with
others. Finally, in the study recruiting children and young adults
the sample included low-grade glioma but also other types of brain
tumours (Jalali 2017).
Surgical interventions
In all studies, most of the included patients had undergone surgical
intervention prior to radio or chemo-therapy although the pro-
portions undergoing biopsy, partial or total resection varied. In the
Jalali 2017 study the number of participants having surgery, and
the type of surgical intervention, was not clear. In the remaining
studies the proportions in treatment groups undergoing the differ-
ent interventions was similar, except for the non-randomised stud-
ies by Klein 2002/Douw 2009 and Vigliani 1996. In these obser-
vational studies, there was disparity between treatment groups in
the numbers undergoing different surgical interventions and in the
light of these differences in patient characteristics, between-groups
findings should be interpreted with particular caution. We have
provided more information of the numbers undergoing surgery in
the Characteristics of included studies tables.
Treatment with anti-epileptic drugs
Only one of the included studies reported on the number of par-
ticipants receiving anti-epileptic drugs. In the Klein 2002/Douw
2009 study, 71% of patients in each of the treatment and control
groups, respectively, received medication to prevent seizures.
Comparisons
The nine included studies examined a range of five different com-
parisons, as follows.
• Radiotherapy versus no adjuvant treatment
• Radiotherapy versus chemotherapy
• High-dose versus low-dose radiotherapy
• Standard versus stereotactic conformal radiotherapy
• Chemoradiotherapy versus radiotherapy alone
1. Radiotherapy versus no adjuvant treatment
Two studies are included in this comparison and both used obser-
vational study designs (Klein 2002/Douw 2009; Vigliani 1996).
In Vigliani 1996 allocation was by physician choice and in the
retrospective study by Klein 2002/Douw 2009 there was no in-
formation on how allocation was made. The latter study involved
a simple comparison between those participants that had or had
not been treated with radiotherapy during the study period.
In the Klein 2002/Douw 2009 study the total mean radiotherapy
dose was 55.6 Gy (standard deviation (SD) 6.1) with a fractional
dose of 1.8 Gy to 2 Gy in 86 of the 104 participants. However, in 18
participants the fractional dose was greater than 2 Gy. The control
group were patients with glioma who did not receive radiotherapy.
In the Vigliani 1996 study the radiotherapy dose was 54 Gy to
55.8 Gy in 1.8 Gy fractions over 6 weeks.
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2. Radiotherapy versus chemotherapy
Reijneveld 2016 examined outcomes in participants randomised
to either receiving radiotherapy (50.4 Gy in 28 fractions of 1.8 Gy
up to 6.5 weeks) versus oral temozolomide daily for 21 out of 28
days repeated for up to 12 cycles (hence the duration of treatment
was quite different in the two experimental groups).
3. High-dose versus low-dose radiotherapy
Two randomised studies examined higher versus lower total doses
of radiotherapy; in both studies, although the fractional doses in
the two arms were the same, the treatment period was longer in the
higher dose groups (Brown 2003; Kiebert 1998). In Brown 2003
the total dose in the higher dose group was 64.8 Gy in 36 fractions
over seven weeks compared with 50.4 Gy in 28 fractions over five
and a half weeks weeks in the lower dose group. In Kiebert 1998
the higher dose was 59.4 Gy over six weeks compared with a lower
dose of 45 Gy over five weeks.
4. Standard versus stereotactic conformal radiotherapy
This comparison included only one study that mainly recruited
children under 16 years of age, but included a subgroup of partici-
pants between 16 and 25 years old (Jalali 2017). The radiotherapy
dose in both arms was 54 Gy in 30 fractions over six weeks.
5. Chemoradiotherapy versus radiotherapy alone
Three studies examined the effects of chemoradiotherapy versus
radiotherapy alone. In all studies the chemotherapy regimen com-
prised procarbazine, lomustine and vincristine. Radiotherapy was
the same in both arms of each trial, although the dose used in the
two studies was different. In the Prabhu 2014 trial, the radiother-
apy dose was a total of 54 Gy in 30 fractions of 1.8 Gy over six
weeks; while in the Taphoorn 2007 and Wang 2010 studies, the
total dose was 59.4 Gy in fractions of 1.8 Gy. As in the Reijneveld
2016 study above, the duration of chemotherapy meant that the
treatment period was more protracted in the chemoradiotherapy
arms.
Outcomes and follow-up
In this review, we aimed to include studies that reported longer
term (two years or longer) neurocognitive or quality of life out-
comes (or both). Several of the studies reported cognitive changes
or impairment using the MMSE (Mini Mental State Examination)
(Brown 2003; Prabhu 2014; Reijneveld 2016; Wang 2010). An
MMSE score of 26 or lower out of 30 was the threshold applied as
indicative of neurocognitive impairment in most of these studies.
For the rest, Jalali 2017 collected data on intelligence quotients
(for participants < 16 years), memory (Wechsler Memory Scale
for participants > 16 years), and anxiety and depression; Vigliani
1996 used a battery of 12 neuropsychological tests and patients
were considered globally deteriorated or improved when at least
eight of 12 items were significantly modified by more than one
standard deviation; and Klein 2002/Douw 2009 reported cogni-
tive disability defined as deficits in at least five of 18 applied neu-
ropsychological tests. Kiebert 1998, Reijneveld 2016, Taphoorn
2007 and Wang 2010 reported quality of life (QoL) outcomes.
Periods of follow-up varied in these studies; while all studies fol-
lowed up participants beyond two years, the number of partici-
pants at each progressive follow-up point was reduced due to death
or disease progression. For example, Brown 2003 followed up par-
ticipants for a mean of 7.4 years but by this time more than half of
the original sample had died (101/203 alive). In the Wang 2010
trial, median follow-up time was 6.9 years in the surviving partic-
ipants but 64% of participants had died, and in Taphoorn 2007
data from 2.5 years after radiotherapy were reported, by which
point 59% of the original sample had died, and data on 32 of the
long-term survivors were reported in 2014. In Klein 2002/Douw
2009 the median follow-up period was 12 years but the treatment
groups were assessed at different time points and, in the inter-
vention group, (radiotherapy) participants had received radiother-
apy up to 20 years previously making results difficult to interpret.
Vigliani 1996 reported outcomes up to four years after treatment.
Kiebert 1998 followed up participants annually from two years;
however, the published report contained QoL outcome data for
participants between seven and 15 months only, which could not
be used for our review purposes.
Excluded studies
After initial screening and full assessment of study reports we ex-
cluded 43 studies from the review. Fifteen studies were excluded
as they did not assess or report neurocognitive or quality of life
outcomes (Buglione 2014; Cairncross 2006; Combs 2008; Dai
2011; Ding 2017; Ediebah 2015; Eyre 1993; Goda 2017; Karim
2002; Malmstrom 2017; MRC 2001; Satoer 2014; Thomas 2001;
van den Bent 2006; Wick 2009). Frequently in these studies the
outcomes of interest were survival and disease progression. In eight
studies all participants or a large proportion had high-grade glioma
such as glioblastoma, and in those studies where some participants
had lower grade glioma separate results were not reported for these
patients (Ali 2018; Chung 2018; NCT02655601; Repka 2018;
Sichez 1996; Wheeler 2016; Wirsching 2018; Zhu 2017). In the
study by Williamson 2017, participants had recurrent glioma and
were undergoing re-irradiation after initial treatment; this study
also included participants with glioblastoma. Packer 2002 looked
at a paediatric population which is outside the remit of this review.
Other important reasons for exclusion related to study design or
the way results were reported. There were five observational studies
with no comparator arm (Anand 2012; Armstrong 2002; Gregor
1996; Shaw 2006; Taylor 1998); and in a further five studies the
control groups were not relevant to the aims of the review (e.g. the
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comparator group were healthy controls or had other types of dis-
ease or malignancy (Archibald 1994; Corn 2009; Costello 2004;
Johannesen 2003; Sherman 2016)). In the study by Correa 2008
that included participants that had received radiotherapy, results
were not analysed or reported separately for the radiotherapy arm
which made results difficult to interpret. Issues relating to study
design and sample selection also meant that results in Surma-aho
2001 were difficult to interpret and likely to be at high risk of bias.
Finally six studies were excluded as they did not report original
study data but were either reviews, commentary or letters to jour-
nal editors (Behrend 2014; Brown 2003b; Brown 2009; Klein
2004; Lunsford 2001; Taphoorn 1994); these reports may have
included reference to studies already included or excluded from
the review.
Risk of bias in included studies
See Figure 3 for the risk of bias summary table.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In the seven RCTs, the methods used to randomise participants to
experimental groups were mainly low risk or not clearly described.
In four studies randomisation was carried out centrally and in
these studies we assessed sequence generation and allocation con-
cealment as low risk of bias (Jalali 2017; Kiebert 1998; Reijneveld
2016; Taphoorn 2007). In Brown 2003, there was probably cen-
tralised randomisation but this was not entirely clear. In the studies
by Prabhu 2014 and Wang 2010, methods of sequence generation
and allocation concealment were not well described (assessed as
unclear risk of bias for both domains).
In the two non-randomised studies there was likely to have been
high risk of selection bias. In Vigliani 1996 allocation was down
to physician choice and there were disparities between groups in
terms of patient characteristics. For Klein 2002/Douw 2009, again
without random allocation there was a likelihood of bias although
methods were not described.
Blinding
In the randomised trials, blinding staff and participants was gen-
erally not feasible as treatment regimens in groups were different.
Blinding of outcome assessment was also likely to have been at
high risk of bias due to lack of blinding, as in this review we focus
on subjective outcomes. Four studies were assessed as high risk
of bias for both performance and detection bias (Prabhu 2014;
Reijneveld 2016; Taphoorn 2007; Wang 2010). Brown 2003 and
Kiebert 1998 did not mention blinding and it was unclear whether
there was any attempt to blind those collecting outcomes to treat-
ment allocation. Jalali 2017 had no treatment masking but re-
ported that investigators collecting outcome data were unaware of
treatment group.
In the non-randomised studies there was no blinding (Klein
2002/Douw 2009; Vigliani 1996). In Klein 2002/Douw 2009,
participants may have been unaware that their data were being
used in a study as data were collected as part of clinical assessment.
In Vigliani 1996, physicians chose treatment and recorded out-
comes.
Incomplete outcome data
All of these studies were assessed as being at high risk of bias
for sample attrition (defined by attrition of more than 20%; see
Appendix 2). In Wang 2010 there was serious sample attrition but
the investigators attempted to take sample loss into account in their
analysis. For the rest, by two to three years following treatment
there was a significant loss to follow-up (with a half or more of the
sample suffering disease progression or death). In Prabhu 2014
and Reijneveld 2016 there was considerable sample loss and at
some assessment points there were different response rates in the
two arms of these trials.
Selective reporting
Selective reporting bias is not easy to assess and this is reflected in
our judgements, with all of the randomised studies being assessed
as unclear risk of bias for this domain.
For the non-randomised studies, we assessed Klein 2002/Douw
2009 as unclear risk of bias and Vigliani 1996 as high risk of bias.
Other potential sources of bias
Risk of other bias was generally not clear. In the Taphoorn 2007
trial progression-free survival was better in one of the treatment
arms and this may have affected some outcomes. In the non-
randomised studies there were baseline differences between groups
(Klein 2002/Douw 2009; Vigliani 1996).
Effects of interventions
See: Summary of findings for the main comparison
We were not able to combine results in meta-analysis due to dif-
ferences in treatment comparisons, time points of follow-up, and
the different outcomes reported. However, we have entered data
applicable to primary outcomes on forest plots, without totals, for
narrative synthesis purposes. Due to the paucity of data available
we have produced a single ’Summary of findings’ table covering
several different comparisons (Summary of findings for the main
comparison). The table includes dichotomous data for our pri-
mary outcome (neurocognitive impairment) for all but one of our
comparisons (the Jalali 2017 study mainly recruited children and
the limited data we summarise in the text below is for a subgroup
aged over 16 years). We did not include estimates of absolute risk
as part of our ’Summary of findings’ table; this was because we
considered that such estimates could be misleading. Findings re-
ported in the review were based on subsets (progression-free sur-
vivors) of samples originally recruited. As sample sizes at follow-
up tended to be small and event rates for outcomes low, there was
considerable uncertainly in effect estimates. Absolute risks would
reflect these serious uncertainties in the relative effect of interven-
tions and were unlikely to be helpful in the interpretation of find-
ings.
We had intended producing a ’Summary of findings’ table for
outcomes relating to quality of life but there were insufficient data
to create a meaningful summary.
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Primary outcomes
Cognitive impairment at 2 years or more after
diagnosis/treatment
A. Radiotherapy versus no radiotherapy
A.1. Radiotherapy versus no adjuvant treatment
Two observational studies contributed data (Klein 2002/Douw
2009; Vigliani 1996), with the Klein 2002/Douw 2009 study
authors reporting two time points up to 12 years after diagnosis/
treatment, and Vigliani 1996 reporting the results of a battery of
cognitive functioning tests from follow-up up to four years after
diagnosis/treatment. In the Klein 2002/Douw 2009 cohort, at the
12-year follow-up, the risk of cognitive impairment (defined as
cognitive disability deficits in at least five of 18 neuropsychological
tests) was greater in the radiotherapy group; at five to six years the
difference between groups did not reach statistical significance (at
five to six years, RR 1.38, 95% CI 0.92 to 2.06; n = 195; at 12
years, RR 1.95, 95% CI 1.02 to 3.71; n = 65) (Figure 4). In the
Vigliani 1996 study, one study subject in the radiotherapy group
had cognitive impairment at two years compared with none in the
control group. We judged the evidence from these observational
studies suggesting a possible negative relative effect of radiotherapy
on long-term cognitive impairment to be of very low certainty.
Figure 4. Forest plot of comparison A. Radiotherapy versus no radiotherapy, outcome: Neurocognitive
impairment at 2 or more years after treatment. (dichotomous data)
With regard to neurocognitive scores, in the later Klein 2002/
Douw 2009 study report (Douw 2009), the radiotherapy group
had significantly worse mean executive functioning, attentional
functioning and processing speed than the group that received
no radiotherapy (Figure 5) and psychomotor functioning, verbal
memory and working memory were reported as not significantly
different; however, the raw data of the non-significant findings
were not given. In Vigliani 1996, there were no clear differences
in any of the various cognitive outcomes measured at two years
(n = 31) and four years (n = 15) after diagnosis. We judged this
evidence as very low certainty due to inconsistency between these
studies.
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Figure 5. comparison A. Radiotherapy versus no radiotherapy, outcome: Neurocognitive impairment at 2
or more years after treatment. (continuous data)
A.2. Radiotherapy versus chemotherapy
One RCT contributed data on cognitive impairment, assessed at
three years after randomisation (Reijneveld 2016). There was no
clear difference in the proportion of participants with cognitive
impairment between the trial arms at this time point (RR 1.43,
95% CI 0.36 to 5.70, n = 117) (Figure 4). MMSE scores were
also measured at different time points and changes from baseline
in MMSE scores up to 36 months were presented in a graph,
with authors reporting that “no significant difference was recorded
between the groups for the change in MMSE scores during the
36 month follow up” (p1533). Sparse data due to attrition and
the wide 95% CIs for findings (imprecision) led us to judge the
certainty of this evidence as low.
B. High-dose radiotherapy versus low-dose radiotherapy
Only one of the two studies - Brown 2003 and Kiebert 1998 -
reporting this comparison contributed data. In the observational
Brown 2003 study, only a small proportion of study subjects ex-
perienced a clinically significant decrease in MMSE score from
baseline (more than 3 points) at the 2- and 5-year follow-ups and
there were no clear differences between high- and low-dose radio-
therapy arms at either time point (Figure 6). Only 38 subjects of
the original cohort of 203 contributed data at the 5-year follow-
up. We judged the certainty of this evidence of no difference to be
very low.
Figure 6. Forest plot of comparison B: High dose versus low dose radiotherapy, outcome: 2.1
Neurocognitive impairment at 2 years or more after treatment.
C. Conventional radiotherapy versus stereotactic conformal
radiotherapy
One study involving younger people with low-grade glioma con-
tributed limited data from the subgroup aged 16 to 25 years (Jalali
2017). The numbers of participants with neurocognitive impair-
ment at five years after treatment, assessed by the Wechsler Mem-
ory Scale, were two out of 12 versus none out of 11 participants in
the conventional radiotherapy and conformal radiotherapy arms,
respectively (Figure 7). These findings are inconclusive because
the study was not powered to detect a difference in this subgroup
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of its participants (RR 4.62, 95% CI 0.25 to 86.72; n = 23; low-
certainty evidence).
Figure 7. Forest plot of comparison C: Conventional versus stereotactic conformal radiotherapy, outcome:
Neurocognitive impairment at 2 years or more after treatment.
D. Chemoradiotherapy versus radiotherapy
Two RCTs reported cognitive impairment based on MMSE mea-
surements for this comparison.
Prabhu 2014 defined it as a decline (of more than 3 points in
MMSE score) in cognitive state compared with baseline and re-
ported comparative data for 2-year (110 participants), 3-year (91
participants), and 5-year (57 participants) time points (Figure 8);
these dichotomous data showed no clear difference between the
two study arms at any time point.
Figure 8. Forest plot of comparison D: Chemoradiotherapy versus radiotherapy, outcome: Neurocognitive
impairment at 2 years or more after treatment.
Wang 2010 reported little raw data. Graphic representation of
mean MMSE scores up to five years suggested that there was little
difference between groups at any time point and authors reported
that there was no difference between MMSE scores between the
two study arms (P = 0.4752). Those assessed at two, three, four,
and five years numbered 126, 110, 69 and 53 survivors respectively
in this study. Only 29 out of 191 had completed all assessments
at five years for the assessment of cognitive function (MMSE).
Authors also reported that the group that received chemoradio-
therapy had improving MMSE scores after two years, whereas in
the radiotherapy-only group mean MMSE scores among survivors
remained constant over time.
We judged the findings (of no difference) to be low-certainty evi-
dence due to risk of (attrition) bias and imprecision.
A 2014 Taphoorn 2007 publication reported no difference in
cognitive impairments between surviving patients treated initially
with radiotherapy and chemoradiotherapy (7 and 20 patients, re-
spectively) at a median survival of 147 months; however data were
not reported separately.
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Quality of life
We found no data on this outcome for comparisons A to C.
D. Chemoradiotherapy versus radiotherapy
Two RCTs involving people with grade 3 gliomas reported qual-
ity of life outcomes for this comparison. One reported no differ-
ences in Brain-QoL scores between its two study arms over a 5-
year follow-up period ( P = 0.2767; no raw data were given and
denominators are not stated) (Wang 2010).
The other trial reported that the long-term results of health-related
quality of life (HRQoL) ”showed no difference between the arms“
but did not give the raw data for overall HRQoL scores (Taphoorn
2007). However, authors reported appetite loss, fatigue, nausea
and vomiting, physical functioning and drowsiness QoL mean
scores; and at 2.5 years after radiotherapy there was no difference
between the groups for any of these HRQoL components among
participants with data at this time point (55 in the chemoradio-
therapy arm and 39 in the radiotherapy arm).
We graded this evidence as low certainty because participants with
progressive disease were excluded from assessment in these stud-
ies. Survivors in the chemoradiotherapy arms outnumbered the
survivors in the radiotherapy arms and those with disease progres-
sion would be expected to experience a worse HRQoL; therefore
the findings are biased towards no difference when there might be
one.
Secondary outcomes
None of the review’s secondary outcomes were reported.
D I S C U S S I O N
Summary of main results
We included nine studies altogether: these compared radiotherapy
versus no adjuvant treatment (2 observational studies), radiother-
apy versus chemotherapy (1 RCT), high-dose radiotherapy ver-
sus low-dose radiotherapy (subgroup analysis of patients without
disease progression from 2 RCTs), conventional radiotherapy ver-
sus stereotactic conformal radiotherapy (1 RCT) and chemora-
diotherapy versus radiotherapy (3 RCTs). All studies except for
those of chemoradiotherapy versus radiotherapy involved people
with low-grade gliomas; whereas two of the chemoradiotherapy
trials involved people with grade 3 glioma. As review outcomes
are long-term outcomes (2 or more years after treatment), attri-
tion was high in most studies and, even in the RCTs, long-term
data were observational because the benefits of randomisation were
lost through attrition. We did not perform meta-analysis because
the studies reported different time points and outcomes; however,
where possible we entered data into forest plots to facilitate narra-
tive synthesis, evidence grading and discussion.
Radiotherapy versus no radiotherapy
For cognitive impairment at two or more years after treatment
(measured as a categorical variable in 3 studies), limited evidence
suggested that radiotherapy may increase the risk of long-term
cognitive impairment; however the magnitude of this effect was
not estimable and we graded the evidence as ’very low certainty’.
Evidence on the associated continuous variables that comprised
different components of cognitive functioning were also very low
certainty. We found no comparative data on quality of life.
High-dose versus low-dose radiotherapy
Only one study contributed data on cognitive impairment at two
and five years after treatment and its findings showed no difference
between these radiotherapy options (very low certainty evidence).
Conventional radiotherapy versus stereotactic
conformal radiotherapy
Low-certainty evidence suggested there may be little or no dif-
ference in cognitive impairment at five years after randomisation
between these options.
Chemoradiotherapy versus radiotherapy alone
Low-certainty evidence suggested there may be little or no differ-
ence between these options in cognitive impairment among sur-
vivors at two and five years’ follow-up. The evidence also suggested
that there may also be little or no difference in quality of life at two
years or more among glioma survivors who receive either treat-
ment option (low-certainty evidence).
We identified no relevant data on the review’s secondary outcomes
or for the brief economic commentary.
Overall completeness and applicability of
evidence
With regard to radiotherapy versus no radiotherapy, the included
studies were fairly old so this very low to low-certainty evidence of
an increased risk of cognitive impairment might not be applicable
to modern radiotherapy techniques, such as image-guided and
conformal radiotherapy, which aim to reduce radiation exposure
to normal tissue.
Findings on the cognitive effects of high-dose versus low-dose
radiotherapy were inconclusive; however, in these studies, death
rates and toxicity rates were slightly but consistently higher in the
high-dose arms. As high-dose radiotherapy in low-grade glioma is
not advocated, further studies on this are unlikely.
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Evidence from studies of radiotherapy versus chemotherapy or
chemoradiotherapy suffered from high attrition and insensitive
measurement tests. Data from various studies employing better
measurement tests are not yet mature (Klein 2017).
With regard to conventional radiotherapy versus stereotactic con-
formal radiotherapy, we derived evidence relating to the review’s
primary outcomes from a group of young participants (aged 16 to
25 years) in only one trial and, unfortunately, the findings were
underpowered to be conclusive. Further research among adult
populations with low-grade glioma would be of interest. Whilst
neuroendocrine dysfunction was measured in this study, we were
unsuccessful in obtaining separate data from the authors for the
subgroup of patients older than 16 years with glioma.
We were unable to synthesise evidence on secondary review out-
comes due to a lack of data.
Quality of the evidence
The main review results suggesting that radiotherapy may have a
negative effect on cognitive functioning in the long term should
be interpreted with caution because the quality of the evidence is
low.
Evidence on cognitive function was most commonly derived from
study data collected using the MMSE, which lacks sensitivity to
mild changes in cognitive impairment and changes due to focal
lesions. This is an important limitation of the evidence, as neu-
rocognitive problems related to brain tumours can be subtle or
restricted to certain neurocognitive domains only (as suggested by
the Klein 2002/Douw 2009 data), depending on their location
(Day 2016).
Brief economic commentary
To supplement the main systematic review of the long-term com-
plications of radiotherapy in those with glioma we sought to iden-
tify economic evaluations which included the long-term effects of
radiotherapy as part of the evaluation. No economic studies were
identified that analysed the long-term consequences of radiother-
apy. The apparent shortage of relevant economic evaluations in-
dicates that economic evidence regarding the long-term effects of
radiotherapy on long-term glioma survivors is needed.
Potential biases in the review process
Whilst we did not pool data, it might have been reasonable to do
so for the primary dichotomous outcome ’Cognitive impairment
at 2 years or more after treatment’ of the ’Radiotherapy versus no
radiotherapy’ comparison. We included three studies in this for-
est plot, two comparing radiotherapy with no adjuvant treatment
and one comparing radiotherapy with chemotherapy. We chose
not to pool these data because of the clinical heterogeneity (dif-
ferent measurement time points and different control interven-
tions). Had we done so (using the 5- to 6-year data from Klein
2002/Douw 2009, not the 12-year data; see Figure 9) the effect
estimate in favour of no radiotherapy would have been an RR of
1.40 (95% CI 0.95 to 2.05). With downgrading for imprecision
and risk of bias, we would most likely have graded this evidence
as low certainty. Whilst our narrative synthesis does not provide
an overall effect estimate, the grading and interpretation of the
evidence is reasonably consistent with the latter.
Figure 9. Forest plot of comparison A (exploratory with totals): Radiotherapy versus no radiotherapy,
outcome: Neurocognitive impairment at 2 or more years after treatment.
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Other potential biases are as follows.
• Neurocognitive impairment was variously measured across
included studies. We extracted and analysed both dichotomous
and continuous data where available. As it is possible for
differences in mean scores between treatment groups to be
statistically significant but not clinically meaningful, evidence on
changes in continuous data (mean scores) should be - and were -
interpreted with caution.
• In the Klein 2002/Douw 2009 study, which reported 12-
year follow-up data (Douw 2009), only the significant results
were reported as raw data in the text. Psychomotor functioning,
verbal memory, and working memory were not significant (data
shown in graphs) but the results tended to be in the same
direction (favouring the ’no radiotherapy’ group). We did not
attempt to obtain these numerical data from the authors as we
considered that any data obtained would be of a very low quality
and did not warrant the (investigator’s) efforts required to retrieve
it, given that the findings were at high risk of bias anyway.
• We included Kiebert 1998, which compared high-dose
radiotherapy with low-dose radiotherapy; however, the study
ended up contributing no usable data to the review. Whilst the
study methods stated that participants were followed up annually
after 24 months, only data from participants between 7 and 15
months after diagnosis were reported in the published paper and
we were unable to obtain any subsequent follow up data.
Findings from the 7- to 15-month assessment showed no
significant difference in neurological impairment and no
significant difference in the proportion of patients with the worst
neurological scores (data were not shown in the paper). There
was no significant difference in QoL scores overall but some QoL
items were worse with high dose, namely emotional functioning
and leisure time activities (P = 0.009 and P = 0.017,
respectively). By not using these data, we might have missed an
opportunity to estimate the effects of high-dose versus low-dose
radiotherapy on quality of life outcomes.
• Prabhu 2014, which compared chemoradiotherapy with
radiotherapy, in addition to reporting neurocognitive decline,
reported the numbers of participants in each group that
experienced an improvement in cognitive functioning (based on
a 3-point increase in MMSE score) over a 5-year period.
Similarly, Vigliani 1996 reported cognitive improvement
according to author-specified criteria in two patients in this
study following radiotherapy. As cognitive improvement was not
a pre-specified outcome, we did not present or analyse these data.
• We included a trial of conventional radiotherapy versus
stereotactic conformal radiotherapy, a more recent radiotherapy
technique that aims to reduce the radiation exposure of normal
tissue; however this trial was conducted mainly in younger
people (Jalali 2017). The sample mainly comprised children and
young people with glioma but also included other brain tumours
including craniopharyngioma. Most results were not broken
down by diagnosis or age group and we were unable to obtain
additional data for the subgroup of interest from study authors.
In this study, most participants were under 16 years but one-
third were aged 16 to 25 years, and we limited our data
extraction to the older age group. Overall, however,
neurocognitive (intelligence quotient or memory scores) of
patients in the stereotactic conformal radiotherapy arm were
either stable or showed an improvement over five years compared
with patients in the conventional radiotherapy arm (difference in
slope = 1.48; P = 0.04), which was the same direction of the
neurocognitive effect reported for the older subgroup only, but
for which the data were sparse. This trial also reported the
incidence of new endocrine dysfunctions, which were
significantly fewer in the stereotactic conformal arm compared
with the conventional arm (52% versus 29%; P = 0.02); we did
not use these data in the review, however, because they were
derived mainly from patients under 16 years old and we were
unsuccessful in obtaining subgroup data from the authors.
• We excluded studies of glioblastoma because of the poor
rates of survival at two years and more. However, with improved
survival rates for IDH-mutated gliomas, useful long-term data
might become available from such studies in the future and we
might need to reconsider our study inclusion/exclusion criteria.
Agreements and disagreements with other
studies or reviews
Two cohort studies (Boele 2015 and Habets 2014) reported
additional long-term data related to included studies (Klein
2002/Douw 2009 and Taphoorn 2007, respectively) for survivors
as a group, rather than separately by treatment group. Both of
these longer term studies compared HRQoL in glioma patients
(low-grade glioma (LGG) and grade 3 patients, respectively) with
healthy controls and previous assessments. Habets 2014 also as-
sessed cognitive functioning. In Boele 2015, the assessments were
at around six and 12 years after diagnosis and initial treatment,
respectively, and in Habets 2014 assessment was at a median of
147 months after diagnosis. Neither of these studies had compar-
ative data that could be included in our meta-analyses. Their main
findings are as follows.
Boele 2015 found that LGG patients had lower physical role func-
tioning (P = 0.004) and general health perceptions (P = 0.004), but
no other statistically significant differences were observed com-
pared with healthy controls. In the majority of patients both phys-
ical (87.7%) and mental (80%) HRQoL remained stable; how-
ever, the mean physical HRQoL score was reported to be signifi-
cantly worse at 12 years than at six years (49.5 versus. 46.9, P <
0.01). Authors concluded that ”although HRQoL remains mostly
preserved in the majority of LGG patients, a subset of patients ex-
perience detectable decline on one or more HRQoL scales despite
long-term stable disease.“
Habets 2014 reported findings of 32 out of 37 long-term sur-
vivors of grade 3 gliomas who had participated in the Taphoorn
2007 trial comparing radiotherapy with chemoradiotherapy. The
number of survivors was less than 10% of the original sample and
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about a third of those assessed at 2.5 years. Ten out of 32 patients
evaluated had received radiotherapy initially, the rest had received
chemoradiotherapy. Compared with healthy controls, survivors
who had never progressed had lower working memory capacity,
information processing speed, psychomotor functioning, atten-
tion, and executive functioning. Investigators reported that initial
treatment did not correlate with HRQoL or cognitive functioning
findings and that HRQoL in the long term for this cohort was
similar to the findings at 2.5 years.
With such studies, it is important to bear in mind that differences
between glioma patients and healthy controls could be related to
the glioma itself, as well as to treatment. Also, long-term data
on cognitive effects and quality of life are inherently biased by
the effect of a given treatment on survival. This is particularly
relevant to studies that show substantial differences in survival,
as quality of life would plausibly be worse among patients with
a shorter survival time at a particular time point distant from
treatment, and cognitive data would be influenced by the greater
attrition of participants in the study arm with the shorter survival.
Such a positive correlation between survival and quality of life is
evident in the Wang 2010 study, which evaluated the effect of
chemoradiotherapy versus radiotherapy alone among people with
anaplastic oligodendrogliomas, and also in CATNON 2017 (see
below).
Ongoing studies
The review process identified six ongoing studies that hope-
fully will contribute data to a future version of this review
(Characteristics of ongoing studies). Ongoing randomised trials
include long-term neurocognitive outcomes of the EORTC study
22033-26033 (radiotherapy versus temozolomide; Klein 2017);
CATNON 2017 (radiotherapy versus radiotherapy plus adju-
vant temozolomide and other comparisons 4 study arms); and
NCT03180502 (proton beam versus intensity-modulated radio-
therapy). Ongoing observational studies include NCT00457210,
NCT02544178 and NCT03055364; one of these was registered
in 2007 and forthcoming data would seem unlikely at this stage.
All the other studies are likely to report results from 2020 onwards.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low-certainty evidence suggests that in good-prognosis patients
with lower grade glioma, radiotherapy may increase the risk of
neurocognitive side effects in the long term; however the magni-
tude of the risk is uncertain. The long-term neurocognitive effects
of adding chemotherapy to radiotherapy are also uncertain. In
general, there were insufficient data to detect possible differences
between groups, and a lack of evidence of effect does not provide
evidence of no effect. Doctors should make patients aware that
radiotherapy may increase the risk of neurocognitive problems,
bearing in mind that cognitive deterioration can also occur with
tumour progression. This review found no evidence on endocrine
dysfunction following radiotherapy and more research on this po-
tential treatment-related effect is needed.
Implications for research
To improve the certainty of evidence around long-term cognitive
effects, neurocognitive assessment should be an integral part of
long-term follow-up in trials of lower grade glioma. Such evalu-
ation should not exclude patients with disease progression, oth-
erwise long-term findings might under-estimate the positive ef-
fects on these outcomes for treatments that improve survival. On-
going studies, such as CATNON 2017, that help to distinguish
which types of glioma respond to more or less aggressive thera-
pies will hopefully lead to improvements in the management of
this condition and reduce any undesirable side effects associated
with overtreatment. Trials should also include systematic long-
term evaluation of endocrine function, particularly in light of a re-
cent report suggesting a high prevalence (Kyriakakis 2019). High-
quality comparative studies should include economic evaluations
that reflect the long-term treatment side effects.
In terms of the types of neurocognitive data that are most useful,
more comprehensive neuropsychological tests, or tests selected to
examine cognitive domains considered likely to be most vulnera-
ble, are preferable to the brief MMSE because they are likely to be
more sensitive to subtle neurocognitive changes and the selective
neurocognitive impairment that occurs due to focal lesions. Day
2016 provides a helpful discussion about test choices.
Finally, a qualitative review on patients’ and carers’ views and ex-
periences of treatment for low-grade glioma would be of value to
improve our understanding of what is important to the individuals
affected by this condition.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2003
Methods Design: primary study was an RCT for which outcomes were previously reported (Shaw
2002). Cognitive function data from the subgroup of participants without tumour pro-
gression were analysed in the Brown 2003 substudy
Country: USA
Accrual dates: 1986 to 1994
Trial reg: NCCTG 86-72-51
Funding: Public Health Service grant nos. CA-25224, CA-37404, CA-15083, and CA-
35415, and the Linse Bock Foundation, Rochester, MN
Participants No. randomised: 211
No. analysed: 203
Inclusion/exclusion criteria: to be eligible, patients had to be 18 years of age or older
and have histologic proof of a supratentorial Kernohan grade 1 or 2 astrocytoma, oligo-
dendroglioma, or mixed oligoastrocytoma within 3 months of study entry (pilocytic
astrocytomas and other LGG variants were excluded)
Age: approx. 50% ≥ 40 years
Gender: 42% female
Glioma type: LGGs (astrocytoma, oligodendroglioma or mixed)
Glioma grade: grade 1 (10), grade 2 (193)
Resection/biopsy: gross total resection (29), subtotal resection (71), biopsy (103)
Anti-epileptics/SSRIs: NR
Duration of FU: median follow-up for the cognitive function study was 7.4 years in 101
patients still alive. At the time of the Shaw 2002 analysis, 83 patients (41%) were dead,
and median follow-up was 6.43 years in the 120 participants who were still alive
Interventions Arm 1: (n = 101) low-dose RT 50.4 Gy in 28 fractions over 5.5 weeks
Arm 2: (n = 102) high-dose RT 64.8 Gy in 36 fractions over 7 weeks
After progression, patients could receive chemotherapy off protocol
Outcomes Reported review outcomes: neurocognitive effects as measured by an MMSE score,
change from baseline, change of more than 3 points considered significant
Other reported study outcomes: Neurologic Function Score (0 to 4)
Evaluations were completed at study entry and then every 4 months for 2 years, every 6
months for 3 years, and yearly until year 15
Notes Neurologic Function Scores were not reported according to randomisation group
Authors conclusions: ”In this population, most low-grade glioma patients maintained a
stable neurocognitive status after focal radiotherapy as measured by the MMSE. Patients
with an abnormal baseline MMSE were more likely to have an improvement in cogni-
tive abilities than deterioration after receiving radiotherapy. Only a small percentage of
patients had cognitive deterioration after radiotherapy. However, more discriminating
neurocognitive assessment tools may identify cognitive decline not apparent with the
use of the MMSE.“
Death rates and toxicity rates were slightly but consistently higher in the high-dose arm
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than the low-dose arm, but the differences were not statistically significant
Of the 5 MMSE domains (orientation, short-term memory retention, attention, short-
term memory recall, language), the most frequently affected (over time in the study
population) were those of language and orientation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The main paper states ”an adaptive strati-
fied randomisation method was used“ and
central randomization likely, but this is not
stated
Allocation concealment (selection bias) Unclear risk Not described in the study reports
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and personnel is
unlikely but this is not described in the
study reports
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in the study reports
Incomplete outcome data (attrition bias)
All outcomes
High risk 97/145 patients without tumour progres-
sion had data for the year 1 assessment,
65/95 patients without tumour progression
had data for year 2, and 38/76 patients
without tumour progression had data for
year 5. The number of participants with
data differed between the groups, particu-
larly for the year 2 assessment when 62% of
data were from the low-dose arm and 38%
from the high-dose arm
Selective reporting (reporting bias) Unclear risk Neurologic Function Scores were assessed
but not reported according to randomisa-
tion group
Other bias Low risk None noted
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Jalali 2017
Methods Design: RCT
Country: single centre study in Mumbai, India
Accrual dates: April 2001 to March 2012
Trial reg: NCT00517959
Funding: reported no conflict of interest. Funded by Tate Memorial Centre and Terry
Fox India and the Brain Tumor Foundation of India. It was stated that the funders had
no influence on the design or conduct of the study
Participants No. randomised: 200 children were randomised. Only 66 were more than 16 years and
results for the over-16 age group are very limited
No. analysed: results for 23 patients over 16 for IQ at 5 years (overall there were 142
measured with neurological outcomes and 181 with endocrine outcomes)
Inclusion/exclusion criteria: children and young adults (up to age 25) with low-grade
and benign residual and/or progressive brain tumours (< 7 cm and require RT, NPS 0
to 3)
Age: median age 13 (3 to 25 years). Sample included 66 young adults over 16 years (45
aged 16 to 20 years and 21 aged 21 to 25 years)
Gender: gender distribution in the sample aged over 16 years not clear, over all age groups
approximately 65% (133) male and 35% (67) female
Glioma type: glioma type for those over 16 years not clear. Overall the sample included
patients with craniopharyngioma, astrocytoma, optic pathway gliomas, ependymoma,
and other tumours
Glioma grade: low grade (grade 2) and benign
Resection/biopsy: not clear
Anti-epileptics/SSRIs: not clear
Duration of FU: up to 5 years (at 6 months, 2, 4, and 5 years)
Interventions Arm 1: Conventional radiotherapy at a dose 54 Gy in 30 fractions over 6 weeks (total
104, with n = 31 participants over 16, but results were available for only 12 at 5 years)
Arm 2: Conformal radiotherapy at a dose 54 Gy in 30 fractions over 6 weeks (total 96
with n = 35 participants over 16 but results were available for only 11 at 5 years)
Outcomes Review outcomes: IQ, memory, depression and anxiety, endocrine function (but results
available for over-16s for findings of the Wechsler Memory Scale only)
Other reported study outcomes: survival
Notes We extracted data only for the 66 young adults over 16 years (45 aged 16 to 20 years and
21 21 to 25 years); these data were scant and we were unable to obtain any additional
data from the authors by email request
Authors reported that in the conformal stereotactic radiotherapy group IQ scores were
either stable or showed some improvement over 5 years compared with the conventional
radiotherapy arm; in the latter arm scores improved in the first 6 months and gradually
declined, reaching pre-radiotherapy baseline scores by the second year and remaining
stable thereafter
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer generated. Stratified by tumour
location, pre or post puberty, neurologi-
cal performance and presence of hydro-
cephalus
Allocation concealment (selection bias) Low risk Allocation and enrolment was carried out
by an external organisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Staff performing intervention would be
aware of allocation. It was not clear whether
patients were aware
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It was stated that outcome assessment was
performed by staff unaware of allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk There was considerable loss to follow-up
that was not explained
Selective reporting (reporting bias) Unclear risk This is a registered trial and expected out-
comes are reported although means and
median scores over the broad age range may
not be meaningful in the context of this re-
view
Other bias Unclear risk For the group of interest to the review most
results are not reported (and subgroup re-
sults may not represent overall findings -
the sample was not stratified by age)
Kiebert 1998
Methods Design: sub-study of a RCT
Country: multinational sites 14 out of 27 sites contributed to the QoL substudy
Accrual dates: April 1985 to September 1991
Trial reg: EORTC 22844 (Karim 1996)
Funding: NR
Participants No. randomised: 379
No. analysed: 109 of 113 that complete a baseline QoL questionnaire
Inclusion/exclusion criteria: all adult patients (age 16 to 65 years) having a definite
histopathologic diagnosis of low-grade astrocytomas (G1 and G2), oligodendroglioma,
and mixed oligoastrocytomas of the supratentorial areas. Grade 1 (pilocytic) astrocytoma,
if totally excised, was excluded, while grade 2 astrocytoma, even if totally excised, was in-
cluded. Oligodendrogliomas and mixed oligoastrocytomas were included. The patients
had to have been in reasonable good general condition as indicated by performance score
after surgery: Karnofsky index ≥ 60 and WHO score ≤ 2. Neurologic deficit status was
also recorded and defined: 1 = no deficit; 2 = some deficit but with adequate function-
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ing for useful work; 3 = moderate functional impairment with movement difficulties,
moderate dysparesis, paresis, and visual or memory impairment; 4 = major functional
impairment; and 5 = lack of conscious response. The patients in categories 4 and 5 were
excluded from this trial. Patients with pregnancy or gross hepatic, renal, or cardiovascular
diseases of malignancy other than curable skin cancers were excluded. However, patients
thought to be cured of cancer for at least 5 years before inclusion in the protocol were
eligible
Age: < 35 years (40), 35 to 44 years (35), ≥ 45 years (38)
Gender: low dose: 24 female, 33 male; high dose: 28 female, 28 male
Glioma type: low dose: astrocytoma (37), oligodendoglioma (15), mixed (5); high-dose:
astrocytoma (35), oligodendoglioma (17), mixed (4)
Glioma grade: low dose: 0 or 1 (6), > 1 (51); high dose: 0 or 1 (6), > 1 (50)
Resection/biopsy: low dose: < 50% tumour excised (23), ≥ 50% tumour excised (34);
high dose: < 50% tumour excised (30), ≥ 50% tumour excised (26)
Anti-epileptics/SSRIs: NR
Duration of FU: 2+ years
Interventions Arm 1: (n = 57) low dose RT (45 Gy in 5 weeks)
Arm 2: (n = 56) high dose RT (59.4 Gy in 6 weeks)
Outcomes Reported review outcomes:
QoL (self-reported scale) including physical, social, psychological, and symptom do-
mains. Signs and symptoms were rated using a Likert scale 1 to 4 (4 = severe); Rand
HIS-Physical capacities scale
Other reported outcomes:
Survival (OS, PFS)
Timing of follow up: 3, 6, 12, 18, 24 months and then annually. Data were analysed in
2 time points immediately post RT and at 7 to 15 months
Notes Longer term (2+ year) follow-up data have not been reported because ”compliance with
further follow-up was so poor that analysis of these latter data were considered inappro-
priate“. At the 7 to 15 month follow-up, there was no significant difference in neurolog-
ical impairment observed, and no significant difference was found in the proportion of
patients with the worst neurological scores (data were not shown). Emotional function-
ing and leisure time activities were significantly worse with high dose (P = 0.009 and
P = 0.017, respectively). Authors found no major difference in QoL overall but some
individual QoL items were worse with high-dose RT
In the primary study, high-dose RT did not lead to better survival than low-dose RT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomization with stratification
according to institution and grade
Baseline characteristics of patients that
completed the QoL questionnaires were
not significantly different to those of the
whole sample
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Allocation concealment (selection bias) Low risk ”Central randomization“
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Long-term (2+ year) follow-up data have
not been reported because ”compliance
with further follow-up was so poor that
analysis of these latter data were considered
inappropriate“
Selective reporting (reporting bias) Unclear risk Not possible to make a judgement
Other bias Unclear risk None noted
Klein 2002/Douw 2009
Methods Design: retrospective observational study with controls and long-term follow-up
Country: the Netherlands. Multicentre study.
Accrual dates: February 1997 and January 2000
Trial reg: not an RCT
Funding: reported no conflict of interest and funders had no influence on study design
or conduct. Later follow-up funded by Kaptein Fonds and Schering Plough. Grant from
Dutch Cancer Society (~VU96-1155)
Participants No. randomised: n/a
No. analysed: 195 patients with low-grade glioma for initial assessments, 65 for longer-
term follow-up at a mean of 12 years
Inclusion/exclusion criteria: adult patients with low-grade glioma with no clinical signs
of tumour recurrence at 1 year after diagnosis and primary treatment and no radiological
signs of recurrence 3 months before testing. Radiotherapy patients were only included
if RT had been given within 8 weeks of histological diagnosis. Patients were excluded if
they were treated with corticosteroids or if they were not proficient in the Dutch language
Age: mean age 42.6 (SD12.2) in the group treated with radiotherapy (n = 104) and 38.
7 (SD 11.5) in the ’no radiotherapy’ group (n = 91) (this age difference was statistically
significant)
Gender: male sex 62/104 (60%) in the radiotherapy group and 58/91 (64%) in the non-
treated group
Glioma type: astrocytoma 139/195, oligodendroglioma 43/195, oligoastrocytoma 13/
195
Glioma grade: grades not reported, all described as low-grade glioma
Resection/biopsy: biopsy 55/104 (53%) in the radiotherapy group, 29/91 (32%) in the
non-treated group. Resection 49/104 (47%) versus 62/ 91 (68%) (significant difference
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between groups for surgical interventions)
Anti-epileptics/SSRIs: anti-epileptics 74/104 (71%) versus 65/91 (71%)
Duration of FU: followed up for a median of 12 years. Patients were assessed at different
time points following RT
Interventions Arm 1: 104 had received RT mostly focal. Mean total dose was 55.6 (6.1). Fractional
dose 1.8 Gy to 2 Gy in 86/104 patients, 18/104 received a fractional dose above 2 Gy
Arm 2: (n = 91); patients with low-grade glioma with no early radiotherapy
The study also included adults with haematological malignancies and healthy controls;
these patients are not included in this review
Outcomes Reported review outcomes: Cognitive test data across different cognitive domains (in-
tellectual functioning, perception and psychomotor speed, memory, attention and exec-
utive function)
Other reported study outcomes: Brain tissue atrophy (Postma 2002). Correlation be-
tween brain tissue atrophy and cognitive functioning
Notes In the intervention group, RT was received from 1 to 20 years previously, with a mean
of 6 years after diagnosis
Authors concluded that low-grade glioma patients do have cognitive problems when
compared to healthy controls and to patients with non-CNS cancers, and those who
received radiotherapy had lower functioning than those not in receipt of RT, but cognitive
disability was only found in patients receiving high fraction doses (exceeding 2 Gy)
HRQoL was reported in a subsequent publication (Boele 2015). In this paper, HRQoL
in 65 LGG patients (irrespective of treatment arm) was compared to that of healthy
controls at around 6 and 12 years after diagnosis and initial treatment, respectively, and
change of time was also assessed. Compared with healthy controls, LGG patients had
lower physical role functioning (P = 0.004) and general health perceptions (P = 0.004),
but no other statistically significant differences were observed. The majority of patients
maintained a stable level of both physical (87.7%) and mental (80%) HRQoL. However,
the mean physical HRQoL score was reported to be significantly worse at 12 years than
at 6 years (49.5 versus. 46.9, P < 0.01). Authors concluded that ”although HRQOL
remains mostly preserved in the majority of LGG patients, a subset of patients experience
detectable decline on one or more HRQOL scales despite long-term stable disease.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational study; non-randomised. Pa-
tients were not allocated to a treatment ran-
domly
Allocation concealment (selection bias) High risk Observational study; non-randomised. No
allocation concealment. Patients not al-
located to a treatment by research team.
Treatment depended on the recruiting cen-
tre; therapeutic policies differed as regards
the use of early physiotherapy and irra-
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diated patients were recruited from cen-
tres where early radiotherapy was favoured.
There may have been other important dif-
ferences in the characteristics of centres and
treatment choices
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Observational study; non-randomised. No
blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Observational study; non-randomised. No
blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk Observational study; non-randomised.
There was considerable loss to follow-up
Selective reporting (reporting bias) Unclear risk Unable to make a judgement
Other bias High risk Representativeness and comparability of
study groups:
Radiotherapy treated patients were older
(the number of years since diagnosis was
also slightly greater (mean difference 1 year)
). Neurosurgical interventions were also
significantly different between groups with
a higher proportion of biopsies in the ra-
diotherapy treated group (52.9% versus 31.
9% in the non-treated group) and a lower
proportion of resections (47.1% versus 68.
1%). The patients in the study with haema-
tological cancers may not be representative
of all such patients - more of this group
than the glioma group declined to partici-
pate, which might have introduced a selec-
tion bias (18% versus 28%)
Baseline differences:
There were also other differences in base-
line characteristics of the two groups which
may indicate that intervention or compar-
ison participants were not representative.
The participants appeared representative in
terms of clinical characteristics
There was an attempt to match groups by
premorbid IQ.
Other bias:
For longer-term follow-up there was con-
siderable attrition due to death, disease pro-
40Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Klein 2002/Douw 2009 (Continued)
gression and other reasons. 65/195 were
followed up at mean 12 years (data pre-
sented in this review). There was a very
broad range of follow-up times. This makes
results more difficult to interpret
Prabhu 2014
Methods Design: RCT (with observational arm - non-randomised)
Country: USA. Multicentred
Accrual dates: 31 October 1998 to 27 June 2002, with long-term follow-up (results up
to 5 years reported in the published paper)
Trial reg: NCT00003375
Funding: it was reported that there was no commercial sponsorship, but in ’Conflicts
of interest’ it appeared that several investigators had received compensation from com-
mercial organisations: Pharmacyclics, Merck Serono, Genentech, Bristol-Myers Squibb,
Merck, Novartis, Elekta, GlaxoSmithKline. It was not clear whether the compensation
was outside this study. NIH funding
Participants No. randomised: (254 originally randomised) 251 eligible for evaluation
No. analysed: 230 included in analyses of cognitive function
Inclusion/exclusion criteria: WHO grade 2 glioma age 40 or more with any extent of
resection or less than 40 with subtotal resection/biopsy. (Histologically confirmed grade
2 astrocytoma, oligodendroglioma or mixed oligoastrocytoma). Karnofsky performance
status 60% or greater, neurological functioning score 3 or less and supratentorial location
Age: median age in RT arm 40 and 41 in RT + chemotherapy. Range overall 18 to 82
(ages 18 to 39 with subtotal resection or 40 or more with total resection and KPS > 60
and neuro ≤ 3)
Gender: male 77/126, female 49/126 in RT arm, male 65/125 and female 60/125 in
RT + Chemo + RT (lower proportion of females (39% ) in RT arm versus 48% in RT
+ chemo arm (NS))
Glioma type: confirmed grade 2 astrocytoma (65) , oligodendroglioma (107) or mixed
oligoastrocytoma (79)
Glioma grade: grade 2 (low grade)
Resection/biopsy: biopsy 119/251, partial resection 107/251, total resection 25/251
Anti-epileptics/SSRIs: not stated.
Duration of follow-up: results up to year 5 reported for cognitive outcomes (survival
follow-up ongoing). At 4, 8,12, 18 and 24 months and annually thereafter. MMSE
evaluated at each follow-up point but discontinued with tumour progression
Interventions Arm 1: (n = 128 randomised, 122 analysed) radiotherapy alone (54 Gy in 30 fractions
of 1.8 Gy) over 6 weeks
Arm 2: (n = 125 randomised, 116 analysed) radiotherapy plus chemotherapy. Following
radiotherapy (as arm 1) patients received 6 cycles of procarbazine (60 mg/m² orally per
day on days 8 and 21 of each cycle), lomustine (110 mg/m² on day 1 of each cycle) and
vincristine (1.4 mg/m² (maximum 2 g) IV on days 8 and 29 of each cycle. The cycle
length was 8 weeks
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Outcomes Reported review outcomes: cognitive function assessed by MMSE at 1, 2, 3 and 5 years
from randomisation. Significant MMSE decline was defined as a decrease of more than
3 points and gain as an increase in score of more than 3 points compared with baseline
Other reported study outcomes: survival reported in main trial report
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Published papers and trial registration do
not state how randomisation was carried
out
Allocation concealment (selection bias) Unclear risk Described as randomised trial with paral-
lel assignment and randomisation stratified
by tumour type but methods of allocation
concealment were not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was described as an open label trial with
no masking in the trial registration
Blinding of outcome assessment (detection
bias)
All outcomes
High risk For some outcomes (survival), lack of
masking may not have been important, but
for assessment of cognitive function lack of
blinding may have introduced bias
Incomplete outcome data (attrition bias)
All outcomes
High risk There was considerable loss to follow-up
due to death and a large proportion of pa-
tients (approximately 1/3) had no MMSE
assessment at 1 year. There seems to have
been fewer responses at all time points in
the radiotherapy plus chemotherapy arm
Selective reporting (reporting bias) Unclear risk The trial was registered but there was very
little information about methods
Other bias Unclear risk It was not explained why large numbers of
patients were not assessed using the MMSE
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Methods Design: Results of follow-up of RCT
Country: 19 countries (Australia, Austria, Belgium, France, Germany, Hungary, Italy, the
Netherlands, Portugal, Spain, Sweden, Switzerland, Australia, New Zealand, Singapore,
Canada, Egypt, Israel, UK)
Accrual dates: December 2005 to December 2012
Trial reg: EudraCT. Number 2004-002714-11 and Clinical/Trials.gov, number
NCT00182819
Funding: Merck Sharp & Dohme, Merck & Co (study chemotherapy drugs and grant),
National Cancer Institute, Swiss Cancer League, National Centre for Health Research,
Cancer Research UK, Canadian Cancer Research Institute, National Health and Medical
Research Council, European Organisation for Research and Treatment of Cancer, Cancer
Research Fund. It was stated that the funders of the research had no role in study design,
data collection, data analysis, data interpretation or writing the report
Conflict of interest: two investigators report personal fees from Hoffmann La Roche
outside the submitted work. One author reports grants and non financial support from
Roche, Ipsen, and Astra-Zeneca outside the submitted work. One author reports grants
from Celgene, Novartis and Pharmamar and personal fees from Celgene, Boehringer,
Genentec, Lilly and Merck-Serono outside the submitted work. Grants from funders as
above
Participants No. randomised: 477 assigned
No. analysed: reported that 477 in ITT analyses (but considerable amounts of missing
data for outcomes relevant to this review)
Inclusion/exclusion criteria:
Age: adults aged 18 years or more (median, 43 (36 to 52 interquartile range) in the
radiotherapy group and 45 (37 to 53) in the chemotherapy group; 38% (92/240) less
than 40 in the radiotherapy group and 36% (85/237) in the chemotherapy group)
Gender: 58% men and 42% women in both groups.
Glioma type: Astrocytoma WHO grade II 37% in the radiotherapy group and 33% in
the chemotherapy group. Oligoastrocytoma WHO grade II 24% and 25%, Oligoden-
droglioma WHO grade II 39% and 41%
Glioma grade: low-grade glioma confirmed 95% and 89%.
Resection/biopsy: radiotherapy: biopsy 40%, partial removal 44%, total removal 15%;
chemotherapy: biopsy 39%, partial removal 42%, total removal 19%
Anti-epileptics/SSRIs: reason for treatment: refractory seizures 12% and 14%
Duration of FU: time between biopsy or surgery to study treatment median 4.8 months
in both groups but considerable variation (2.9 to 18.3 IQR months in the radiotherapy
group and 2.6 and 26.4 months in the chemotherapy group). Time from initial diagnosis
and study treatment medians 5.1 and 6.0 months
Interventions Arm 1: (n = 240) radiotherapy. Total dose of 50.4 Gy in 28 fractions of 1.8 Gy once
daily for 5 days per week up to a maximum treatment period of 6.5 weeks. Reasons for
treatment discontinuation included major worsening of neurological or mental status or
other medical condition that would preclude continuation. Dose adjustments were not
recommended
Arm 2: (n = 237) chemotherapy. 75 mg/m² oral temozolomide daily for 21 of 28 days
(1 cycle) repeated for a maximum of 12 cycles until disease progression or unacceptable
toxicity. The treatment was withheld if low neutrophil and platelet counts and resumed
on recovery. Patients with severe recurrent toxicity despite dose reduction discontinued
treatment
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Outcomes Reported review outcomes: adverse events, health-related quality of life (HRQoL scales
including global health or quality of life status, role and functioning, social functioning,
communication deficit, visual disorder, motor dysfunction, drowsiness) and cognitive
functioning (MMSE). Outcomes reported up to 36 months
Other reported study outcomes: Primary outcome of trial was progression-free survival
Notes Authors emailed 6 February 2019.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation using a minimi-
sation technique (stratified for WHO per-
formance status, age, presence or absence
of contrast enhancement on MRI, 1p sta-
tus, and treatment centre
Allocation concealment (selection bias) Low risk Probably low risk as randomisation was
centralised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk There was no attempt to blind participants
and staff as treatments were different. The
different types of treatment may have af-
fected patient compliance
Blinding of outcome assessment (detection
bias)
All outcomes
High risk For self-assessed outcomes relevant to this
review the different treatments may have
affected response rates and those experi-
encing worse outcomes may have been less
likely to respond. It was reported that re-
sponse was lowest in patients with poor per-
formance status
Incomplete outcome data (attrition bias)
All outcomes
High risk For long-term outcomes relevant to this re-
view response rates were less than 70% at
2 years; for early assessments response rates
were greater in the chemotherapy group al-
though this disparity between groups de-
creased over time. Denominators for some
outcomes were not clear. There was varia-
tion between treatment centres in response
rates
Selective reporting (reporting bias) Unclear risk This was a registered trial with specified
outcomes using standard measures. The
frequency of testing may have introduced
risk of multiple testing
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Other bias Unclear risk Treatment modalities differed significantly
in duration and intensity and early differ-
ences detected in QoL may have reflected
these differences in treatment modalities
Taphoorn 2007
Methods Design: RCT
Country: Multicentre study in 40 hospitals in Europe (the Netherlands, France, Austria,
Hungary, Italy, Belgium)
Accrual dates: August 1996 to March 2002
Trial reg: European Organisation for Research and Treatment of Cancer (EORTC)26951
Funding: authors report no conflict of interest. Supported by EORTC Grant , Astra
Zeneca, and Dutch Cancer Society
Participants No. randomised: 368 patients randomised.
No. analysed: QoL data available for 288 patients at baseline and 94 patients at follow-
up at 2.5 years
Inclusion/exclusion criteria: patients aged 16 to 70 years diagnosed with anaplastic oligo-
dendroglioma or mixed oligoastrocytoma with at least 25% oligodendroglial elements
and at least 3 or 5 anaplastic characteristics (high cellularity, mitosis, nuclear abnormal-
ities, endothelial proliferation and necrosis); patients had performance status 0 to 2 and
had not undergone previous chemotherapy or radiotherapy to the skull, had no other
diseases interfering with follow-up and had adequate haematologic, renal and hepatic
function
Age: median in radiotherapy plus chemotherapy group 48.6 (range 18.6 to 68.7), Median
in radiotherapy only group 49.8 (range 19.2 to 68.7)
Gender: male/female sex, 102/83 in the radiotherapy plus chemotherapy group and 110/
73 in the radiotherapy only group. Overall 58% male
Glioma type: oligodendroglioma (265/ 368) or mixed oligoastrocytoma (100/368)
(pathology missing for 3 patients)
Glioma grade: not clear
Resection/biopsy: all patients had surgery. biopsy 52/368; partial resection 183, total
resection 133
Anti-epileptics/SSRIs: not clear
Duration of FU: 2.5 years for quality of life outcomes. (59% patients died by this time)
Interventions Arm 1: (n = 185) radiotherapy plus chemotherapy. Radiotherapy within 6 weeks of
surgery dose 45 Gy to the planning target volume in 25 daily fractions of 1.8 Gy 5
fractions a week. After that a boost of 14.4 Gy up to a cumulative dose of 59.4 Gy in
8 fractions of 1.8 Gy. Chemotherapy was 6 cycles of standard procarbazine, lomustine
and vincristine to start within 4 weeks after the end of radiotherapy. Cycle consisted of
lomustine 110 mg/m² orally on day 1 with antiemetics, procarbazine 60 mg/m² orally
on days 8 to 21 and vincristine 1.4 mg/m² IV on days 8 to 29 (maximum dose 2 mg).
Cycles were repeated every 6 weeks with dose reductions
Arm 2: (n = 183) radiotherapy as above without adjuvant chemotherapy
Disease progression led to 54 patients in the RT/PCV group and 85 in the RT group
having other chemotherapy
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Taphoorn 2007 (Continued)
Outcomes Reported review outcomes: quality of life (EORTC quality of life questionnaire C30
with specific brain cancer module with 20 topics relevant to brain tumour). Cognitive
function (Mini mental status examination - but results not reported in published papers)
. Fatigue, nausea, physical functioning, appetite loss, drowsiness. Reported at baseline
and 3-monthly. For this review, outcomes at 1 year, 2 years and 2.5 years reported
Other reported study outcomes: survival, progression-free survival
Notes SDs were calculated for HRQoL scores where possible.
Long-term HRQoL and cognitive functioning in a cohort of survivors was reported in
a subsequent paper (Habets 2014). Results of 32 patients were compared to healthy
controls and to their earlier findings at 2.5 years. Findings showed that 31% were severely
cognitively impaired; HRQoL was worse compared with controls but similar to their
HRQoL at the 2.5 year assessment. Authors concluded that ”In progression-free patients,
HRQOL is relatively stable during the disease course.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External randomisation service (EORTC)
data centre (computer randomisation via
the internet or phone). Stratified by age,
extent of resection, performance score and
previous surgery
Allocation concealment (selection bias) Low risk External randomisation service (EORTC)
data centre (computer randomisation via
the internet)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible and it is not clear
whether lack of blinding affected other
treatment decisions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Some outcomes may not have been affected
by lack of blinding but it is possible quality
of life outcomes were affected
Incomplete outcome data (attrition bias)
All outcomes
High risk Due to death and disease progression there
was considerable loss to follow-up at the
later assessments. Less than half of those
randomised had recurrent disease or had
died by 30 months. (149/368 still alive and
progression free; of these 94/149 returned
QoL assessment forms)
Selective reporting (reporting bias) Unclear risk Cognitive outcomes were not reported in
published papers
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Taphoorn 2007 (Continued)
Other bias Unclear risk Progression-free survival was increased in
the radiotherapy plus chemotherapy (but
not overall survival): this may have had an
impact on findings if 1 group remained
healthier for slightly longer. (This was
stated in the paper as a possible bias in
HRQoL assessments.)
Vigliani 1996
Methods Design: cohort of patients either treated with radiotherapy or not
Country: single hospital in France
Accrual dates: February 1989 to December 1993
Trial reg: not a trial
Funding: Associazione Italiana per la Ricerca sul Cancro (AIRC) Milan, and EEC Ra-
dioprotection Program Grant. Conflict of interest not stated
Participants No. randomised: not randomised. Total 31. Irradiated group 17, no radiotherapy 14
No. analysed: decreasing numbers over time; at 1 year 29, 2 years 21, 3 years 15 and 4
years 11
Inclusion/exclusion criteria: patients attending a Paris hospital with low-grade glioma or
anaplastic astrocytoma with good prognostic factors (total or subtotal resection, age <
60 years, Karnofski index > 70)
Age: radiotherapy group mean 35.3 (range 24 to 49), no radiotherapy 37.7 years (16 to
56 years)
Gender: M/F radiotherapy group 12/5, no radiotherapy 12/2
Glioma type: in radiotherapy group 11 had astrocytoma, 1 mixed glioma, 1 oligoden-
droglioma, 1 anaplastic oligodendroglioma and 3 anaplastic astrocytoma. In the non-
radiotherapy group it was stated all had low-grade astrocytoma (in 8 cases diagnosis was
available - 4 astrocytomas, 2 mixed gliomas and 2 oligodendrogliomas)
Glioma grade: grade II and III described as low grade with good prognosis
Resection/biopsy: in the radiotherapy group 2 had total resection, 8 partial resection
and 7 biopsy. In the ’no radiotherapy’ group 4 had total resection, 3 partial resection, 1
biopsy and 6 patients had no biopsy
Anti-epileptics/SSRIs: not mentioned
Duration of FU: annually up to 4 years
Interventions The decision whether or not to use radiotherapy was made by the physician caring for
the patient
Arm 1: (n = 17) radiotherapy. Limited field radiotherapy (tumour bed and 2 cm to 3 cm
margin) dose 54 Gy to 55.8 Gy in 1.8 Gy fractions (30 to 31) over 6 weeks. (In addition
4 patients had chemotherapy.)
Arm 2: (n = 14) no radiotherapy (and none had chemotherapy)
Outcomes Reported review outcomes: neuropsychological tests - battery of tests administered by
a neuropsychologist (Stroop color word test, WAIS subtest code, reaction time, verbal
span, visual span, Raven progressive matrices (PM38), Wechsler memory scale, recall of
word series, recall of design, recall of Rey-Osterrieth complex figure). Testing 120 to 150
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Vigliani 1996 (Continued)
minutes at yearly intervals for 4 years (radiotherapy group also tested at 6 months)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The decision to administer radiotherapy
was made by the attending physician.
Those receiving radiotherapy may have dif-
ferent (worse diagnoses) or groups may not
have been treated by the same doctors with
some doctors being more or less likely to
opt for radiotherapy. 6 of the ’no radiother-
apy’ group had no histologically confirmed
diagnosis
Allocation concealment (selection bias) High risk The decision to administer radiotherapy
was made by the attending physician.
Those receiving radiotherapy may have dif-
ferent (worse diagnoses) or groups may not
have been treated by the same doctors with
some doctors being more or less likely to
opt for radiotherapy. 6 of the ’no radiother-
apy’ group had no histologically confirmed
diagnosis
Blinding of participants and personnel
(performance bias)
All outcomes
High risk 6/14 had no clear diagnosis. No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk There was considerable attrition over time
with 11/31 assessed at 4 years. (15/31 at 3
years.)
Selective reporting (reporting bias) High risk Reporting by doctors who selected treat-
ment
Other bias High risk There were no significant differences re-
ported although groups were too small to
identify possible differences. Age and sex
were similar. It was not clear if type of
glioma were the same in the two groups
and there were differences in rates of neuro-
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Vigliani 1996 (Continued)
logical resection/biopsy. There were some
differences in neuropsychological scores
at baseline (IQ and reaction time). The
changes were assessed at the individual level
(ANOVA) but group means were reported
and with serious sample attrition these are
not simple to interpret
Wang 2010
Methods Design: randomised controlled trial
Country: 76 institutions in USA and Canada
Accrual dates: 1994 to 2002 with long-term follow-up
Trial reg: Radiation Therapy Oncology Group Trial 9402. NCT 00002569
Funding: Radiotherapy oncology group grants, North Central Cancer Treatment Group
Grant, Eastern Cooperative Oncology Group Grant, Southwest Oncology Group Grant,
Community Clinical Oncology Program Grant, National Cancer Institute, National
Cancer Institute of Canada
Authors state no conflict of interest
Participants No. randomised: 291
No. analysed: 291. No patients were lost to follow-up but due to death and other factors
the number analysed at different time points decreased over time. Only 29/191 had
completed all assessments at 5 years for the assessment of cognitive function (MMSE)
Inclusion/exclusion criteria: patients 18 years or more with confirmed diagnoses of
anaplastic oligodendroglioma and anaplastic oligoastrocytoma with Karnofsky perfor-
mance status 60 or more after surgery, adequate marrow and organ function, not preg-
nant and with no other serious illness
Age: Median age in ’chemotherapy plus radiotherapy’ group 43 (range 18 to 75) and in
the radiotherapy group median 43 (range 19 to 76)
Gender: MF; radiotherapy plus chemotherapy group 90/58; radiotherapy alone 84/59
(approximately 60% male in both groups)
Glioma type: anaplastic oligodendroglioma 150/291; anaplastic oligoastrocytoma 141/
291
Glioma grade: grade III. 161 had moderately anaplastic disease and 130 highly anaplastic
Resection/biopsy: total resection in the CRT and RT alone groups 40/148 and 53/143;
partial resection 85 and 75, biopsy only 21 and 14
Anti-epileptics/SSRIs: not stated (corticosteroids at baseline CRT group and 79 in the
RT group
Duration of FU: median survival for surviving patients was 6.9 years (64% had died)
Interventions Arm 1: (n = 148) chemotherapy and radiotherapy. Chemotherapy within 1 week of
randomisation. 4 cycles every 6 weeks before radiotherapy: lomustine 130 mg/m² orally
on day 1, procarbazine 75 mg/m² orally daily days 8 to 21 and vincristine 1.4 mg/m²
IV on days 8 and 29. There was no 2 mg limit on vincristine. Radiotherapy 59.4 Gy in
33 fractions of 1.8 Gy each 5 days a week
Arm 2: (n = 143) radiotherapy alone as above
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Wang 2010 (Continued)
Outcomes Reported review outcomes: Cognitive function MMSE and Quality of life (B-QOL,
Brain Quality of Life,) baseline, 9 and 12 months, 4 monthly in year 2, 6 monthly years
3 to 5 then annually
Other reported study outcomes: survival; toxicity and symptoms were assessed but not
reported in detail or by randomisation group
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not fully described but was a RTOG trial
and randomisation was stratified
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible and staff and patients
would have been aware of randomisation
group. It was not clear whether lack of
blinding would have affected those out-
comes assessed. (It is not clear if those
with radiotherapy alone completed treat-
ment before those receiving chemotherapy.
)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Detection of survival outcomes are unlikely
to have been affected by assignment. Pa-
tients completed forms themselves for cog-
nitive function
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was considerable loss to follow-up
due to death and disease progression. There
was an attempt by the authors to take ac-
count of these factors in analysis and anal-
ysis was mainly relating to within-subject
factors
Selective reporting (reporting bias) Unclear risk Outcomes that may be important to pa-
tients were not reported in full (toxicity,
nausea, etc). Also much of the analysis was
not by randomisation group
Other bias Unclear risk None noted
CNS = central nervous system; EORTC = European Organisation for Research and Treatment of Cancer; Gy = Grays; LGG = low
grade glioma; HGG = high grade glioma; NR = not reported; HRQoL = Health-related quality of life; IQ = intelligence quotient;
ITT = intention to treat; KPS = Karnofsky Performance Score; MMSE = Mini Mental State Examination; NAT = no adjuvant
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treatment; NS = not statistically significant; QoL = quality of life; PFS = progression free survival; OS = overall survival; RCT =
randomised controlled trial; RT= radiotherapy; RTOG = Radiation Therapy Oncology Group; SD = standard deviation; WHO =
World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ali 2018 This trial compared hyperfractionated versus standard radiotherapy for patients with glioma; more than 70%
of participants had glioblastoma
Anand 2012 No comparator arm
Archibald 1994 Wrong comparator arm (healthy controls)
Armstrong 2002 No comparator arm, mixed population
Behrend 2014 Not a study report
Brown 2003b Review article
Brown 2009 Commentary
Buglione 2014 Study of early versus late RT for LGG but only 6 patients had neurocognitive function assessed and neurocog-
nitive scores were not compared between study groups
Cairncross 2006 No neurocognitive outcomes reported
Chung 2018 Paricipants all had glioblastoma
Combs 2008 No neurocognitive outcomes
Corn 2009 Before and after study of different doses of RT with no comparator arm
Correa 2008 Treated patients compared with NAT group included patients who had RT (n = 5), RT plus CT (n = 1) but
also CT only (n = 3). Data on participants who had RT are not reported separately from those who only had
CT
Costello 2004 Wrong comparator (non-malignant tumour group)
Dai 2011 No neurocognitive outcomes reported
Ding 2017 No neurocognitive outcomes reported
Ediebah 2015 No neurocognitive outcomes reported
Eyre 1993 No neurocognitive outcomes reported
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Goda 2017 No neurocognitive data reported
Gregor 1996 No comparator arm
Johannesen 2003 No neurocognitive outcomes reported; no relevant comparison
Karim 2002 No neurocognitive outcomes reported
Klein 2004 Not a study but a letter to the editor
Laack 2005 A cohort study of 20 adults who received radiotherapy (50.4Gy or 64.8Gy) for LGG. Cognitive function was
reported as stable at 3-year follow up, but findings were not reported separately by treatment group
Lunsford 2001 Not a study but a letter to the editor
Malmstrom 2017 All received RT; no late effects data
MRC 2001 All received RT; no late effects neurocognitive outcome data reported
NCT02655601 Study examining participants with high-grade glioma
Packer 2002 Commentary on a paediatric study
Repka 2018 Recruited patients with high-grade glioma and glioblastoma
Satoer 2014 Wrong intervention and no late neurocognitive outcomes reported
Shaw 2006 No comparator arm
Sherman 2016 Wrong comparator (published normals)
Sichez 1996 Wrong population mixed HGG population
Surma-aho 2001 Retrospective study of effects of RT versus no RT but the study groups were highly selected at baseline and so
the findings are impossible to interpret with any certainty
Taphoorn 1994 Not a study but a letter to the editor
Taylor 1998 No comparator arm
Thomas 2001 All received RT; no late effects neurocognitive outcomes data reported
van den Bent 2006 No neurocognitive outcome data reported
Wheeler 2016 Mixed HGG population with low numbers with grade 3; all had RT (question was the effect of immunotherapy)
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(Continued)
Wick 2009 No long-term (> 2 years) neurocognitive outcome data reported
Williamson 2017 This study looked at re-irradiation of patients with recurrent glioma; some had glioblastoma and no neurocog-
nitive outcomes were reported
Wirsching 2018 This trial examined chemoradiotherapy versus radiotherapy alone in elderly patients (ARTE trial). All partici-
pants had glioblastoma
Zhu 2017 All participants in this trial had glioblastoma
Gy = Grays; LGG = low grade glioma; HGG = high grade glioma;nNAT = no adjuvant treatment; RCT = randomised controlled trial;
RT= radiotherapy;
Characteristics of ongoing studies [ordered by study ID]
CATNON 2017
Trial name or title CATNON trial (EORTC study 26053-22054)
Methods Phase 3 randomised, open-label study with 2x2 factorial design. Web-based randomisation (1:1:1:1)
Participants 784 randomised
Patients were 18 years or older with newly diagnosed non-co-deleted anaplastic glioma with WHO perfor-
mance scores of 0 to 2
Interventions RT
RT + adjuvant TMZ
RT + concurrent TMZ
RT + concurrent TMZ + adjuvant TMZ
Outcomes 5-year PFS and OS, adverse events, HRQoL and cognitive effects
Starting date Dec 2007 ongoing
Contact information Martin van den Bent; m.vandenbent@erasmusmc.nl
Notes Interim results were published in 2017, which showed that adjuvant TMZ was associated with significant 5-
year survival benefit in this population. (One might expect that cognitive data will therefore be biased by the
greater attrition in the study arms with adjuvant TMZ)
Neurocognitive data will be presented in 2020/21 (personal communication)
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Klein 2017
Trial name or title Memory functioning in low-grade glioma patients treated with either RT or TMZ EORTC study 22033-
26033
Methods Memory functioning using the Rey Auditory Verbal Learning Test applied at baseline and every 6 months
subsequently, and memory functions compared between treatment arms over time. Minimal compliance was
set at 60%
Participants 98 patients with low-grade glioma were assessed at baseline
Interventions RT 52 participants
TMZ 46 participants
Outcomes Memory functioning (free recall and delayed recall)
Starting date Date is not clear from the conference abstract, in which 12-month data on memory functioning are reported
(no clear difference in memory functioning between RT and TMZ groups at 12 months)
Contact information Martin Klein
Notes Mature data from this study are expected to contribute to the review in due course.Reijneveld 2016
Reijneveld 2016 reports the QoL data for EORTC 22033-26033 and survival data are reported in New
Reference
NCT00457210
Trial name or title The influence of radiotherapy on cognitive function
Methods Prospective observational cross-sectional study
Participants 150 20- to 80-year-old oncologic patients, of both genders, that are referred to brain radiotherapy or stereo-
tactic radiosurgery due to primary brain tumour/brain metastases or increased risk for brain metastases
Interventions (observational) Radiotherapy or sterotactic radiosurgery
Outcomes Cognitive function questionnaire
Starting date April 2007
Contact information bencorn@tasmc.health.gov.il
Notes Study status is unknown and, given the date of registration, publication seems unlikely. No response to email
query
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NCT02544178
Trial name or title Study of neurological complication after radiotherapy for high-grade glioblastoma (EPIBRAINRAD)
Methods Prospective observational cohort
Participants 200 consecutive adult patients treated by radiotherapy and chemotherapy for a glioma stage 3 or 4 in the
Pitié-Salpêtrière Hospital or in the Paul Strauss hospital from April 2015 to April 2017 will be included
Interventions (observational) Treatment by radiotherapy and chemotherapy
Outcomes Primary:
• Decrease in computerised speed cognitive test
Secondary:
• Sensitivity and specificity of computerised speed test
• Dosimetric prognostic factors
• Biomarkers
• Radiologic prognostic factors
Starting date April 2015
Contact information marie-odile.bernier@irsn.fr
Notes Estimated completion date: 2020
NCT03055364
Trial name or title Cognitive function after treatment of primary CNS malignancy
Methods Prospective observational cohort study
Participants 160 people with primary CNS malignancy receiving brain radiotherapy
Interventions (observational) Brain radiotherapy
Outcomes Rate and magnitude of change in cognitive performance within 12 months of completion of therapy in patients
with intracranial malignancies receiving photon- or proton-based cranial irradiation with curative intent (time
frame: baseline, completion of treatment, 3 months, 6 months, 1 year and 2 years after radiotherapy)
Starting date May 2017
Contact information tranby.brianna@mayo.edu
Notes Estimated completion date: May 2021
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NCT03180502
Trial name or title Proton beam or intensity-modulated radiation therapy in preserving brain function in patients with IDH
mutant grade II or III glioma
Methods Phase 2, randomized, parallel arm, open-label trial
Participants Patients with IDH mutant, low to intermediate grade gliomas
Interventions Active Comparator: Arm I (IMRT, temozolomide)
Patients undergo IMRT daily, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after
completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats
every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity
Experimental: Arm II (proton beam radiation therapy, temozolomide)
Patients undergo proton beam radiation therapy daily, 5 days a week for 6 weeks for a total of 30 fractions.
Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide
for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of
unacceptable toxicity
Outcomes Primary:
• Change in cognition (time frame: baseline to up to 10 years)
Secondary:
• Change in quality of life
• Change in symptoms
• Cognition (various scales)
• Adverse events (CTCAE v 4.0)
• Local control
• Overall survival
• Progression-free survival
Starting date 2 August 2017
Contact information Claudine.Gamster@CadenceHealth.org
Notes Estimated completion date: May 2022
CNS = central nervous system; EORTC = European Organisation for Research and Treatment of Cancer; Gy = Grays; IMRT = intensity
modulated radiotherapy; LGG = low grade glioma; HGG = high grade glioma; HRQoL = Health-related quality of life; PFS =
progression free survival; OS = overall survival; RT= radiotherapy; TMZ = temozolomide
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A P P E N D I C E S
Appendix 1. Search strategies
Medline Search Strategy
1. exp Glioma/
2. (glioma* or astrocytoma* or medulloblastoma* or ependymoma* or craniophyrangioma* or oligodendroglioma* or glioblastoma*
or GBM*).ti,ab.
3. 1 or 2
4. exp Radiotherapy/
5. radiotherapy.fs.
6. (radiotherap* or radiat* or irradiat*).ti,ab.
7. exp Antineoplastic Agents/
8. Antineoplastic Combined Chemotherapy Protocols/
9. chemotherap*.mp.
10. exp Chemoradiotherapy/
11. (radiochemo* or chemoradio*).mp.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 3 and 12
14. Radiation Effects/
15. exp Radiation Injuries/
16. adverse effects.fs.
17. ((late or adverse* or long term or side or long-term or chronic* or residual* or delay* or undesirable or unexpected) adj5 (effect*
or event* or outcome* or reaction* or complication* or harm* or injur* or toxic* or cognit*)).ti,ab.
18. (adrs or tolerab*).ti,ab.
19. (radiation induced* or radiation-induced).ti,ab.
20. 14 or 15 or 16 or 17 or 18 or 19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. clinical trials as topic.sh.
26. randomly.ab.
27. trial.ti.
28. exp Cohort Studies/
29. cohort*.tw.
30. longitudinal*.tw.
31. prospective*.tw.
32. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
33. 13 and 20 and 32
34. exp animals/ not humans.sh.
35. 33 not 34
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
Medline Search with economic filter:
1. exp Glioma/
2. (glioma* or astrocytoma* or medulloblastoma* or ependymoma* or craniophyrangioma* or oligodendroglioma* or glioblastoma*
or GBM*).ti,ab.
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3. 1 or 2
4. exp Radiotherapy/
5. radiotherapy.fs.
6. (radiotherap* or radiat* or irradiat*).ti,ab.
7. exp Antineoplastic Agents/
8. Antineoplastic Combined Chemotherapy Protocols/
9. chemotherap*.mp.
10. exp Chemoradiotherapy/
11. (radiochemo* or chemoradio*).mp.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 3 and 12
14. Radiation Effects/
15. exp Radiation Injuries/
16. adverse effects.fs.
17. ((late or adverse* or long term or side or long-term or chronic* or residual* or delay* or undesirable or unexpected) adj5 (effect*
or event* or outcome* or reaction* or complication* or harm* or injur* or toxic* or cognit*)).ti,ab.
18. (adrs or tolerab*).ti,ab.
19. (radiation induced* or radiation-induced).ti,ab.
20. 14 or 15 or 16 or 17 or 18 or 19
21. 13 and 20
22. Economics/
23. exp ”costs and cost analysis“/
24. Economics, Dental/
25. exp economics, hospital/
26. Economics, Medical/
27. Economics, Nursing/
28. Economics, Pharmaceutical/
29. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
30. (expenditure$ not energy).ti,ab.
31. value for money.ti,ab.
32. budget$.ti,ab.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. ((energy or oxygen) adj cost).ti,ab.
35. (metabolic adj cost).ti,ab.
36. ((energy or oxygen) adj expenditure).ti,ab.
37. 34 or 35 or 36
38. 33 not 37
39. letter.pt.
40. editorial.pt.
41. historical article.pt.
42. 39 or 40 or 41
43. 38 not 42
44. 21 and 43
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
Embase Search Strategy
1. exp Glioma/
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2. (glioma* or astrocytoma* or medulloblastoma* or ependymoma* or craniophyrangioma* or oligodendroglioma* or glioblastoma*
or GBM*).ti,ab.
3. 1 or 2
4. exp radiotherapy/
5. radiotherapy.fs.
6. (radiotherap* or radiat* or irradiat*).ti,ab.
7. exp chemotherapy/
8. exp antineoplastic agent/
9. chemotherap*.mp.
10. exp chemoradiotherapy/
11. (radiochemo* or chemoradio*).mp.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 3 and 12
14. radiation response/
15. exp radiation injury/
16. ae.fs.
17. ((late or adverse* or long term or side or long-term or chronic* or residual* or delay* or undesirable or unexpected) adj5 (effect*
or event* or outcome* or reaction* or complication* or harm* or injur* or toxic* or cognit*)).ti,ab.
18. (adrs or tolerab*).ti,ab.
19. (radiation induced* or radiation-induced).ti,ab.
20. 14 or 15 or 16 or 17 or 18 or 19
21. crossover procedure/
22. randomized controlled trial/
23. single blind procedure/
24. random*.mp.
25. factorial*.mp.
26. (crossover* or cross over* or cross-over).mp.
27. placebo*.mp.
28. (doubl* adj blind*).mp.
29. (singl* adj blind*).mp.
30. assign*.mp.
31. allocat*.mp.
32. volunteer*.mp.
33. exp cohort analysis/
34. cohort*.tw.
35. longitudinal*.tw.
36. prospective*.tw.
37. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. 13 and 20 and 37
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
Embase Search with economic filter:
1. exp Glioma/
2. (glioma* or astrocytoma* or medulloblastoma* or ependymoma* or craniophyrangioma* or oligodendroglioma* or glioblastoma*
or GBM*).ti,ab.
3. 1 or 2
4. exp radiotherapy/
5. radiotherapy.fs.
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6. (radiotherap* or radiat* or irradiat*).ti,ab.
7. exp chemotherapy/
8. exp antineoplastic agent/
9. chemotherap*.mp.
10. exp chemoradiotherapy/
11. (radiochemo* or chemoradio*).mp.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. 3 and 12
14. radiation response/
15. exp radiation injury/
16. ae.fs.
17. ((late or adverse* or long term or side or long-term or chronic* or residual* or delay* or undesirable or unexpected) adj5 (effect*
or event* or outcome* or reaction* or complication* or harm* or injur* or toxic* or cognit*)).ti,ab.
18. (adrs or tolerab*).ti,ab.
19. (radiation induced* or radiation-induced).ti,ab.
20. 14 or 15 or 16 or 17 or 18 or 19
21. 13 and 20
22. Health Economics/
23. exp Economic Evaluation/
24. exp Health Care Cost/
25. pharmacoeconomics/
26. 22 or 23 or 24 or 25
27. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
28. (expenditure$ not energy).ti,ab.
29. (value adj2 money).ti,ab.
30. budget$.ti,ab.
31. 27 or 28 or 29 or 30
32. 26 or 31
33. letter.pt.
34. editorial.pt.
35. note.pt.
36. 33 or 34 or 35
37. 32 not 36
38. (metabolic adj cost).ti,ab.
39. ((energy or oxygen) adj cost).ti,ab.
40. ((energy or oxygen) adj expenditure).ti,ab.
41. 38 or 39 or 40
42. 37 not 41
43. 21 and 42
44. (exp animal/ or nonhuman/ or exp animal experiment/) not human/
45. 43 not 44
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
CENTRAL search strategy
#1. MeSH descriptor: [Glioma] explode all trees
#2. glioma* or astrocytoma* or medulloblastoma* or ependymoma* or craniophyrangioma* or oligodendroglioma* or glioblastoma*
or GBM*
#3. #1 or #2
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#4. MeSH descriptor: [Radiotherapy] explode all trees
#5. radiotherap* or radiat* or irradiat*
#6. MeSH descriptor: [Antineoplastic Agents] explode all trees
#7. MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#8. Any MeSH descriptor with qualifier(s): [Radiotherapy - RT]
#9. Any MeSH descriptor with qualifier(s): [Drug therapy - DT]
#10. Chemotherap*
#11. MeSH descriptor: [Chemoradiotherapy] explode all trees
#12. radiochemo* or chemoradio*
#13. #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14. #3 AND #13
#15. MeSH descriptor: [Radiation Effects] this term only
#16. MeSH descriptor: [Radiation Injuries] explode all trees
#17. Any MeSH descriptor with qualifier(s): [Adverse effects - AE]
#18. ((late or adverse* or long term or side or long-term or chronic* or residual* or delay* or undesirable or unexpected) near/5 (effect*
or event* or outcome* or reaction* or complication* or harm* or injur* or toxic* or cognit*))
#19. adrs or tolerab*
#20. radiation induced* or radiation-induced
#21. #15 or #16 or #17 or #18 or #19 or #20
#22. #14 AND #21
Appendix 2. Assessment of risk of bias
For randomised trials
(1) Random sequence generation
• Low risk of bias, e.g. participants assigned to treatments on basis of a computer-generated random sequence or a table of random
numbers
• High risk of bias, e.g. participants assigned to treatments on basis of date of birth, clinic id-number or surname, or no attempt to
randomise participants
• Unclear risk of bias, e.g. not reported, information not available
(2) Allocation concealment
• Low risk of bias, e.g. where the allocation sequence could not be foretold
• High risk of bias, e.g. allocation sequence could be foretold by patients, investigators or treatment providers
• Unclear risk of bias, e.g. not reported
(3) Blinding of participants and personnel
• Low risk of bias if participants and personnel were adequately blinded
• High risk of bias if participants and/or personnel were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
(4) Blinding of outcomes assessors
• Low risk of bias if outcome assessors were adequately blinded to the intervention that the participant received
• High risk of bias if outcome assessors were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
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(5) Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the end of the study. We will code a satisfactory
level of loss to follow-up for each outcome as follows.
• Low risk of bias, if fewer than 20% of patients were lost to follow-up and reasons for loss to follow-up were similar in both
treatment arms
• High risk of bias, if more than 20% of patients were lost to follow-up or reasons for loss to follow-up differed between treatment
arms
• Unclear risk of bias, if loss to follow-up was not reported
(6) Selective reporting of outcomes
• Low risk of bias, e.g. review reports all outcomes specified in the protocol
• High risk of bias, e.g. it is suspected that outcomes have been selectively reported
• Unclear risk of bias, e.g. it is unclear whether outcomes had been selectively reported
(7) Other bias
• Low risk of bias, i.e. no other source of bias suspected and the trial appears to be methodologically sound
• High risk of bias, i.e. we suspect that the trial was prone to an additional bias
• Unclear risk of bias, i.e. we are uncertain whether an additional bias may have been present
For non-randomised trials
We will assess the risk of bias in accordance with four criteria concerning sample selection comparability of treatment groups.
(1) Relevant details of criteria for assignment of participants to treatments
• Low risk of bias, e.g. yes, details provided
• High risk of bias, e.g. no details provided
• Unclear risk of bias, e.g. details unclear
(2) Representative group of people who received the experimental intervention
• Low risk of bias, if representative of patients with gliomas who receive treatment for their condition
• High risk of bias, if groups of patients were selected (non-consecutive)
• Unclear, if selection of the group was not described
(3) Representative group of people who received the comparison intervention
• Low risk of bias, if drawn from the same population as the experimental group
• High risk of bias, if drawn from a different source
• Unclear risk of bias, if selection of group not described
(4) Baseline differences between groups controlled for, in particular with reference to age, gender, grade/type of glioma,
type of surgery
• Low risk of bias, if all of these characteristics were reported
• High risk of bias, if the groups differed in these baseline characteristics and differences were not controlled for
• Unclear risk of bias, if fewer than three of these characteristics were reported even if there were no other differences between the
groups, and other characteristics were controlled for
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We moved the Health-Related Quality of Life (HRQoL) outcome from a secondary outcome in the protocol to a primary outcome in
the review. This facilitated the inclusion of Taphoorn 2007, which reported HRQoL but not neurocognitive outcomes.
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